<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01856595</url>
  </required_header>
  <id_info>
    <org_study_id>B4801003</org_study_id>
    <nct_id>NCT01856595</nct_id>
  </id_info>
  <brief_title>PF-06291874 Multiple Ascending Dose Study In Type 2 Diabetes Mellitus Patients</brief_title>
  <official_title>A Phase 1, Placebo-controlled Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Escalating Oral Doses Of Pf-06291874 In Adults With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability, pharmacokinetics and
      pharmacodynamics of multiple ascending doses of PF-06291874 in Type 2 Diabetes patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 13, 2013</start_date>
  <completion_date type="Actual">March 1, 2014</completion_date>
  <primary_completion_date type="Actual">January 10, 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Had Protocol-Defined Total Hypoglycemic Adverse Event (HAE) - Part A</measure>
    <time_frame>Day 1 up to 7-11 days after last dose of study drug</time_frame>
    <description>A hypoglycemic event (HAE) was identified by characteristic symptoms or blood glucose levels. Hypoglycaemia was assessed and reported in several categories: severe hypoglycaemia, documented symptomatic hypoglycaemia, asymptomatic hypoglycaemia, and probable hypoglycaemia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Had Protocol-Defined Total Hypoglycemic Adverse Event (HAE) - Part B</measure>
    <time_frame>Day 1 up to 7-11 days after last dose of study drug</time_frame>
    <description>A hypoglycemic event (HAE) was identified by characteristic symptoms or blood glucose levels. Hypoglycaemia was assessed and reported in several categories: severe hypoglycaemia, documented symptomatic hypoglycaemia, asymptomatic hypoglycaemia, and probable hypoglycaemia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Electrocardiograms (ECGs) Data Met Criteria of Potential Clinical Concern - Part A</measure>
    <time_frame>Predose (0),4,6,8,12,24 hours on Days 1 and 14; 8 hours post dose on Days 3,7,11 for all Cohorts ; predose on Day 17 for Cohorts 1- 4A and 1B; predose on Days 21 and 28 for Cohorts 5A and 2B.</time_frame>
    <description>ECG criteria of potential clinical concern were 1), PR interval: greater than or equal to (&gt;=)300 milliseconds (msec); &gt;=25 percent (%) increase when baselinegreater than (&gt;)200 msec; or increase &gt;=50% when baseline less than or equal to (&lt;=)200 msec; 2), QRS interval: &gt;=140 msec; &gt;=50% increase from baseline; 3), QT interval: &gt;=500 msec, QTc interval using cridericia's formula (QTcF interval): absolute value &gt;=450 - &lt;480 msec, &gt;=480-&lt;500 msec, &gt;500 msec; absolute change 30 - &lt;60, &gt;=60 msec.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With ECGs Data Met Criteria of Potential Clinical Concern - Part B</measure>
    <time_frame>Predose (0),4,6,8,12,24 hours on Days 1 and 14; 8 hours post dose on Days 3,7,11 for all Cohorts ; predose on Day 17 for Cohorts 1- 4A and 1B; predose on Days 21 and 28 for Cohorts 5A and 2B.</time_frame>
    <description>ECG criteria of potential clinical concern were 1), PR interval: &gt;=300 msec; &gt;=25% increase when baseline &gt;200 msec; or increase &gt;=50% when baseline &lt;=200 msec; 2), QRS interval: &gt;=140 msec; &gt;=50% increase from baseline; 3), QT interval: &gt;=500 msec, QTcF interval: absolute value &gt;=450 - &lt;480 msec, &gt;=480-&lt;500 msec, &gt;500 msec; absolute change 30 - &lt;60, &gt;=60 msec.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Vital Signs Data Met Criteria of Potential Clinical Concern - Part A</measure>
    <time_frame>Predose (0),4,6,8,12,24 hours on Days 1 and 14; 8 hours post dose on Days 3,7,11 for all Cohorts ; predose on Day 17 for Cohorts 1- 4A and 1B; predose on Days 21 and 28 for Cohorts 5A and 2B.</time_frame>
    <description>Vital signs included blood pressure (BP; supine, sitting and standing) and pulse rate. Vital signs criteria of potential clinical concern were 1), BP: systolic BP (SBP) greater than or equal to (&gt;=) 30 millimeters of mercury (mm Hg) change from grand baseline in same posture, systolic less than (&lt;) 90 mm Hg; diastolic BP (DBP) &gt;=20 mm Hg change from grand baseline in same posture, diastolic &lt;50 mm Hg; 2), pulse rate (supine): &lt;40 or greater than (&gt;) 120 beats per minute (bpm).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Vital Signs Data Met Criteria of Potential Clinical Concern - Part B</measure>
    <time_frame>Predose (0),4,6,8,12,24 hours on Days 1 and 14; 8 hours post dose on Days 3,7,11 for all Cohorts ; predose on Day 17 for Cohorts 1- 4A and 1B; predose on Days 21 and 28 for Cohorts 5A and 2B.</time_frame>
    <description>Vital signs included blood pressure (BP; supine, sitting and standing) and pulse rate. Vital signs criteria of potential clinical concern were 1), BP: SBP &gt;= 30 mm Hg change from grand baseline in same posture, SBP &lt; 90 mm Hg; DBP &gt;=20 mm Hg change from grand baseline in same posture, DBP&lt;50 mm Hg; 2), pulse rate (supine): &lt;40 or &gt; 120 bpm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Any Abnormal Laboratory Test Results - Part A</measure>
    <time_frame>Predose on Days 0,3,7,11 for all cohorts and 14 and 17 for Cohorts 1- 4A and 1B, and pre-dose on Days 21 and 28 for Cohorts 5A and 2B.</time_frame>
    <description>The laboratory test included: hematology (hemoglobin, hematocrit, red blood cell count, MCV, MCH, MCHC, platelets, white blood cell count, absolute lymphocytes, absolute total neutrophils, absolute basophils, absolute eosinophils and absolute monocytes), coagulation (PPT, prothrombin), liver function(total bilirubin, AST, ALT, alkaline phosphatase, total protein and albumin), renal function (blood urea nitrogen, creatinine, uric acid), Lipids (cholesterol, HDL cholesterol, LDL cholesterol, triglycerides), Electrolytes (sodium, potassium, chloride, calcium, venous bicarbonate), clinical chemistry (glucose, glycosylated, hemoglobin, amylase, lipase), urinalysis dipstick (urine PH, urine glucose, urine ketones, urine protein, urine urobilinogen, urine bilirubin, urine nitrite, urine leukocyte, esterase), urinalysis microscopy (urine RBC, urine WBC, urine bacteria). Laboratory abnormality was determined by the investigator based on pre-defined criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Any Abnormal Laboratory Test Results - Part B</measure>
    <time_frame>Predose on Days 0,3,7,11 for all cohorts and 14 and 17 for Cohorts 1- 4A and 1B, and pre-dose on Days 21 and 28 for Cohorts 5A and 2B.</time_frame>
    <description>The laboratory test included: hematology (hemoglobin, hematocrit, red blood cell count, MCV, MCH, MCHC, platelets, white blood cell count, absolute lymphocytes, absolute total neutrophils, absolute basophils, absolute eosinophils and absolute monocytes), coagulation (PPT, prothrombin), liver function(total bilirubin, AST, ALT, alkaline phosphatase, total protein and albumin), renal function (blood urea nitrogen, creatinine, uric acid), Lipids (cholesterol, HDL cholesterol, LDL cholesterol, triglycerides), Electrolytes (sodium, potassium, chloride, calcium, venous bicarbonate), clinical chemistry (glucose, glycosylated, hemoglobin, amylase, lipase), urinalysis dipstick (urine PH, urine glucose, urine ketones, urine protein, urine urobilinogen, urine bilirubin, urine nitrite, urine leukocyte, esterase), urinalysis microscopy (urine RBC, urine WBC, urine bacteria). Laboratory abnormality was determined by the investigator based on pre-defined criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Single Dose Maximum Plasma Concentration (Cmax) for PF-06291874 - Part A</measure>
    <time_frame>0 hour (pre-dose), 2, 4, 6, 8, 12, 19, 24 hours post-dose on Day 1</time_frame>
    <description>Cmax was maximum plasma concentration. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for pharmacokinetic (PK) analysis were collected at 0, 2, 4, 6, 8, 12, 19 and 24 hours post dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Single Dose Normalized Cmax (Cmax[dn]) for PF-06291874 - Part A</measure>
    <time_frame>0 hour (pre-dose), 2, 4, 6, 8, 12, 19, 24 hours post-dose on Day 1</time_frame>
    <description>Cmax (dn) was dose normalized maximum plasma concentration. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for pharmacokinetic (PK) analysis were collected at 0, 2, 4, 6, 8, 12, 19 and 24 hours post dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Single Dose Cmax for PF-06291874 - Part B</measure>
    <time_frame>0 hour (pre-dose), 2, 4, 6, 8, 12, 19, 24 hours post-dose on Day 1</time_frame>
    <description>Cmax was maximum plasma concentration. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19 and 24 hours post dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Single Dose Normalized Cmax (Cmax[dn]) for PF-06291874 - Part B</measure>
    <time_frame>0 hour (pre-dose), 2, 4, 6, 8, 12, 19, 24 hours post-dose on Day 1</time_frame>
    <description>Cmax (dn) was dose normalized maximum plasma concentration. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19 and 24 hours post dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Single Dose Time at Which Cmax Occurred (Tmax) for PF-06291874 - Part A</measure>
    <time_frame>0 hour (pre-dose), 2, 4, 6, 8, 12, 19, 24 hours post-dose on Day 1</time_frame>
    <description>Tmax was time at which Cmax occurred. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Single Dose Tmax for PF-06291874 - Part B</measure>
    <time_frame>0 hour (pre-dose), 2, 4, 6, 8, 12, 19, 24 hours post-dose on Day 1</time_frame>
    <description>Tmax was time at which Cmax occurred. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Single Dose AUCtau (Area Under the Concentration-time Profile From Time Zero to Time Tau, the Dosing Interval, Where Tau = 24 Hours) for PF-06291874 - Part A</measure>
    <time_frame>0 hour (pre-dose), 2, 4, 6, 8, 12, 19, 24 hours post-dose on Day 1</time_frame>
    <description>AUCtau was area under the concentration-time profile from time zero to time tau, the dosing interval, where tau = 24 hours. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Single Dose AUCtau for PF-06291874 - Part B</measure>
    <time_frame>0 hour (pre-dose), 2, 4, 6, 8, 12, 19, 24 hours post-dose on Day 1</time_frame>
    <description>AUCtau was area under the concentration-time profile from time zero to time tau, the dosing interval, where tau = 24 hours. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Dose Cmax for PF-06291874 - Part A</measure>
    <time_frame>Predose (0), 2, 4, 6, 8, 12, 19, 24 hours post dose on Day 14</time_frame>
    <description>Cmax was maximum plasma concentration. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Dose Cmax for PF-06291874 - Part B</measure>
    <time_frame>Predose (0), 2, 4, 6, 8, 12, 19, 24 hours post dose on Day 14</time_frame>
    <description>Cmax was maximum plasma concentration. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Dose Tmax for PF-06291874 - Part A</measure>
    <time_frame>Predose (0), 2, 4, 6, 8, 12, 19, 24 hours post dose on Day 14</time_frame>
    <description>Tmax was time at which Cmax occurred. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Dose Tmax for PF-06291874 - Part B</measure>
    <time_frame>Predose (0), 2, 4, 6, 8, 12, 19, 24 hours post dose on Day 14</time_frame>
    <description>Tmax was time at which Cmax occurred. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Dose AUCtau for PF-06291874 - Part A</measure>
    <time_frame>Predose (0), 2, 4, 6, 8, 12, 19, 24 hours post dose on Day 14</time_frame>
    <description>AUCtau was area under the concentration-time profile from time zero to time tau, the dosing interval, where tau = 24 hours. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Dose AUCtau for PF-06291874 - Part B</measure>
    <time_frame>Predose (0), 2, 4, 6, 8, 12, 19, 24 hours post dose on Day 14</time_frame>
    <description>AUCtau was area under the concentration-time profile from time zero to time tau, the dosing interval, where tau = 24 hours. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Dose Half Life for PF-06291874</measure>
    <time_frame>Predose (0), 2, 4, 6, 8, 12, 19, 24 hours post dose on Day 14</time_frame>
    <description>Plasma half-life was the time measured for the plasma concentration to decrease by one half. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Dose Cmin (Lowest Plasma Concentration Observed During the Dosing Interval) for PF-06291874 - Part A</measure>
    <time_frame>Predose (0), 2, 4, 6, 8, 12, 19, 24 hours post dose on Day 14</time_frame>
    <description>Cmin was the lowest plasma concentration observed during the dosing interval. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Dose Cmin for PF-06291874 - Part B</measure>
    <time_frame>Predose (0), 2, 4, 6, 8, 12, 19, 24 hours post dose on Day 14</time_frame>
    <description>Cmin was the lowest plasma concentration observed during the dosing interval. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Dose Apparent Clearance (CL/F) for PF-06291874 - Part A</measure>
    <time_frame>on Day 14 over 2 collection periods (0-6 hours and 6-24 hours).</time_frame>
    <description>CL/F was multiple dose apparent clearance. The 24-hour urine samples for PK analysis were collected on Day 14 over 2 collection periods (0-6 hours and 6-24 hours).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Dose CL/F for PF-06291874 - Part B</measure>
    <time_frame>on Day 14 over 2 collection periods (0-6 hours and 6-24 hours).</time_frame>
    <description>CL/F was multiple dose apparent clearance. The 24-hour urine samples for PK analysis were collected on Day 14 over 2 collection periods (0-6 hours and 6-24 hours).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Dose Apparent Volume of Distribution (Vz/F) for PF-06291874- Part A and Part B</measure>
    <time_frame>Predose (0), 2, 4, 6, 8, 12, 19, 24 hours post dose on Day 14</time_frame>
    <description>Vz/F was apparent volume of distribution. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Dose Observed Accumulation Ratio (Rac) for PF-06291874 - Part A</measure>
    <time_frame>Predose (0), 2, 4, 6, 8, 12, 19, 24 hours post dose on Day 14</time_frame>
    <description>Rac was observed accumulation ratio. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Dose Rac for PF-06291874 - Part B</measure>
    <time_frame>Predose (0), 2, 4, 6, 8, 12, 19, 24 hours post dose on Day 14</time_frame>
    <description>Rac was observed accumulation ratio. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Dose Rac for Cmax (Rac,Cmax) for PF-06291874 - Part A</measure>
    <time_frame>Predose (0), 2, 4, 6, 8, 12, 19, 24 hours post dose on Day 14</time_frame>
    <description>Rac,cmax was observed accumulation ratio for Cmax. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Dose Rac,Cmax for PF-06291874 - Part B</measure>
    <time_frame>Predose (0), 2, 4, 6, 8, 12, 19, 24 hours post dose on Day 14</time_frame>
    <description>Rac,cmax was observed accumulation ratio for Cmax. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Dose Percent of Cumulative Amount of Drug Recovered Unchanged in Urine Over the Dosing Interval τ(Aetau%) for PF-06291874</measure>
    <time_frame>on Day 14 over 2 collection periods (0-6 hours and 6-24 hours).</time_frame>
    <description>Aetau% was percent of cumulative amount of drug recovered unchanged in urine over the dosing interval τ. The 24-hour urine samples for PK analysis were collected on Day 14 over 2 collection periods (0-6 hours and 6-24 hours).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Dose Renal Clearance (CLr) for PF-06291874</measure>
    <time_frame>on Day 14 over 2 collection periods (0-6 hours and 6-24 hours).</time_frame>
    <description>CLr was renal clearance. The 24 hour urine samples for PK analysis were collected on Day 14 over 2 collection periods (0-6 hours and 6-24 hours)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes From Baseline for Mean Daily Glucose (mg/dL) on Day 14 (AUC Approach) - Part A</measure>
    <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 10, 12, 15, 19 and 24 hours on Days -1 and 14 for all cohorts, and on Day 28 for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B.</time_frame>
    <description>A MMTT was administered on Days -1 and 14 for all cohorts. Blood samples for analysis of glucose were collected at nominal time 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 10, 12, 15, 19 and 24 hours on Days -1 and 14 for all cohorts. MDG was computed by AUC24/24 hours of the glucose values measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes From Baseline for Mean Daily Glucose (mg/dL) on Day 14 (AUC Approach) - Part B</measure>
    <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 10, 12, 15, 19 and 24 hours on Days -1 and 14 for all cohorts, and on Day 28 for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B.</time_frame>
    <description>A MMTT was administered on Days -1 and 14 for all cohorts. Blood samples for analysis of glucose were collected at nominal time 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 10, 12, 15, 19 and 24 hours on Days -1 and 14 for all cohorts. MDG was computed by AUC24/24 hours of the glucose values measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes From Baseline for Mean Daily Glucose (mg/dL) on Day 28 (AUC Approach)</measure>
    <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 10, 12, 15, 19 and 24 hours on Days -1 and 14 for all cohorts, and on Day 28 for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B.</time_frame>
    <description>A MMTT was administered on Days -1 for all cohorts, and on Day 28 for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B. Blood samples for analysis of glucose were collected at nominal time 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 10, 12, 15, 19 and 24 hours on Days -1 and 14 for all cohorts, and on Day 28 for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B. MDG was computed by AUC24/24 hours of the glucose values measured.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes Relative to Baseline (Ratio) of AUC0-4 for Glucose Following MMTT on Day 14 - Part A</measure>
    <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 10, 12, 15, and 19 hours on Days -1 and 14 for all cohorts, and on Day 28 for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B.</time_frame>
    <description>Blood samples for analysis of glucose were collected at nominal time 0, 0.25, 0.5, 1, 1.5, 2, 3, and 4 hours on Days -1 and 14 for all cohorts, and on Day 28 for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B. AUC0-4 and natural log transformed AUC0-4 were calculated for each day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes Relative to Baseline (Ratio) of AUC0-4 for Glucose Following MMTT on Day 14 - Part B</measure>
    <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 10, 12, 15, and 19 hours on Days -1 and 14 for all cohorts, and on Day 28 for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B.</time_frame>
    <description>Blood samples for analysis of glucose were collected at nominal time 0, 0.25, 0.5, 1, 1.5, 2, 3, and 4 hours on Days -1 and 14 for all cohorts, and on Day 28 for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B. AUC0-4 and natural log transformed AUC0-4 were calculated for each day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes Relative to Baseline (Ratio) of AUC0-4 for Glucose Following MMTT on Day 28</measure>
    <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 10, 12, 15, and 19 hours on Days -1 and 14 for all cohorts, and on Day 28 for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B.</time_frame>
    <description>Blood samples for analysis of glucose were collected at nominal time 0, 0.25, 0.5, 1, 1.5, 2, 3, and 4 hours on Days -1 and 14 for all cohorts, and on Day 28 for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B. AUC0-4 and natural log transformed AUC0-4 were calculated for each day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Changes From Baseline of AUC0-4 for Glucagon Following MMTT on Day 14 - Part A</measure>
    <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 3, 4 hours on Days -1 and 14 for all cohorts, and on Day 28 and follow-up visit for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B.</time_frame>
    <description>Blood samples for analysis of insulin, C-peptide, glucagon and glucagon-like peptide 1 (GLP-1) were collected at nominal time 0, 0.25, 0.5, 1, 1.5, 2, 3, 4 hours on Days -1 and 14 for all cohorts, and on Day 28 and follow-up visit for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B. AUC0-4 and natural log transformed AUC0-4 were calculated for each day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Changes From Baseline of AUC0-4 for Glucagon Following MMTT on Day 14 - Part B</measure>
    <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 3, 4 hours on Days -1 and 14 for all cohorts, and on Day 28 and follow-up visit for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B.</time_frame>
    <description>Blood samples for analysis of insulin, C-peptide, glucagon and glucagon-like peptide 1 (GLP-1) were collected at nominal time 0, 0.25, 0.5, 1, 1.5, 2, 3, 4 hours on Days -1 and 14 for all cohorts, and on Day 28 and follow-up visit for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B. AUC0-4 and natural log transformed AUC0-4 were calculated for each day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Changes From Baseline of AUC0-4 for Glucagon Following MMTT on Day 28</measure>
    <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 3, 4 hours on Days -1 and 14 for all cohorts, and on Day 28 and follow-up visit for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B.</time_frame>
    <description>Blood samples for analysis of insulin, C-peptide, glucagon and GLP-1 were collected at nominal time 0, 0.25, 0.5, 1, 1.5, 2, 3, 4 hours on Days -1 and 14 for all cohorts, and on Day 28 and follow-up visit for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B. AUC0-4 and natural log transformed AUC0-4 were calculated for each day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes Relative to Baseline (Ratio) of AUC0-4 for Insulin Following MMTT on Day 14 - Part A</measure>
    <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 3, 4 hours on Days -1 and 14 for all cohorts, and on Day 28 and follow-up visit for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B.</time_frame>
    <description>Blood samples for analysis of insulin, C-peptide, glucagon and GLP-1 were collected at nominal time 0, 0.25, 0.5, 1, 1.5, 2, 3, 4 hours on Days -1 and 14 for all cohorts, and on Day 28 and follow-up visit for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B. AUC0-4 and natural log transformed AUC0-4 were calculated for each day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes Relative to Baseline (Ratio) of AUC0-4 for Insulin Following MMTT on Day 14 - Part B</measure>
    <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 3, 4 hours on Days -1 and 14 for all cohorts, and on Day 28 and follow-up visit for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B.</time_frame>
    <description>Blood samples for analysis of insulin, C-peptide, glucagon and GLP-1 were collected at nominal time 0, 0.25, 0.5, 1, 1.5, 2, 3, 4 hours on Days -1 and 14 for all cohorts, and on Day 28 and follow-up visit for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B. AUC0-4 and natural log transformed AUC0-4 were calculated for each day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes Relative to Baseline (Ratio) of AUC0-4 for Insulin Following MMTT on Day 28</measure>
    <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 3, 4 hours on Days -1 and 14 for all cohorts, and on Day 28 and follow-up visit for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B.</time_frame>
    <description>Blood samples for analysis of insulin, C-peptide, glucagon and GLP-1 were collected at nominal time 0, 0.25, 0.5, 1, 1.5, 2, 3, 4 hours on Days -1 and 14 for all cohorts, and on Day 28 and follow-up visit for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B. AUC0-4 and natural log transformed AUC0-4 were calculated for each day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes Relative to Baseline (Ratio) of AUC0-4 for C-Peptide Following MMTT on Day 14 - Part A</measure>
    <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 3, 4 hours on Days -1 and 14 for all cohorts, and on Day 28 and follow-up visit for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B.</time_frame>
    <description>Blood samples for analysis of insulin, C-peptide, glucagon and GLP-1 were collected at nominal time 0, 0.25, 0.5, 1, 1.5, 2, 3, 4 hours on Days -1 and 14 for all cohorts, and on Day 28 and follow-up visit for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B. AUC0-4 and natural log transformed AUC0-4 were calculated for each day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes Relative to Baseline (Ratio) of AUC0-4 for C-Peptide Following MMTT on Day 14 - Part B</measure>
    <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 3, 4 hours on Days -1 and 14 for all cohorts, and on Day 28 and follow-up visit for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B.</time_frame>
    <description>Blood samples for analysis of insulin, C-peptide, glucagon and GLP-1 were collected at nominal time 0, 0.25, 0.5, 1, 1.5, 2, 3, 4 hours on Days -1 and 14 for all cohorts, and on Day 28 and follow-up visit for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B. AUC0-4 and natural log transformed AUC0-4 were calculated for each day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes Relative to Baseline (Ratio) of AUC0-4 for C-Peptide Following MMTT on Day 28</measure>
    <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 3, 4 hours on Days -1 and 14 for all cohorts, and on Day 28 and follow-up visit for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B.</time_frame>
    <description>Blood samples for analysis of insulin, C-peptide, glucagon and GLP-1 were collected at nominal time 0, 0.25, 0.5, 1, 1.5, 2, 3, 4 hours on Days -1 and 14 for all cohorts, and on Day 28 and follow-up visit for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B. AUC0-4 and natural log transformed AUC0-4 were calculated for each day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Values and Changes From Baseline in Fasting Plasma Glucose at at Days 2, 7, 14, 15, 21, 28 and 29 - Part A</measure>
    <time_frame>predose on Days 0,2,7,14,15,21,28,29</time_frame>
    <description>Fasting blood glucose samples were also collected on Days 0, 2, 7, and 15 for all cohorts, and on Days 21 and 29 for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Values and Changes From Baseline in Fasting Plasma Glucose at Days 2, 7, 14, 15, 21, 28 and 29 - Part B</measure>
    <time_frame>Days 0,2,7,14,15,21,28,29</time_frame>
    <description>Fasting blood glucose samples were also collected on Days 0, 2, 7, and 15 for all cohorts, and on Days 21 and 29 for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Values and Changes From Baseline in Fasting Plasma Insulin at Days 14 and 28 - Part A</measure>
    <time_frame>Days -1, 14, 28</time_frame>
    <description>Fasting blood insulin samples were collected on Days -1, 14 and 28 for all cohorts, and on Day 28 for PF-06291874 100 mg Part A. Baseline was defined as the value on Day -1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Values and Changes From Baseline in Fasting Plasma Insulin at Days 14 and 28 - Part B</measure>
    <time_frame>Days -1, 14, 28</time_frame>
    <description>Fasting blood insulin samples were collected on Days -1, 14 and 28 for all cohorts, and on Day 28 for PF-06291874 30 mg Part B. Baseline was defined as the value on Day -1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Lipid Parameters (mg/dL) by Treatment Group on Days 14 and 28 - Part A</measure>
    <time_frame>Days 0,14 and 28</time_frame>
    <description>Blood samples (3.5 mL) for all lipids and 2 mL for ApoB100 were collected at Hour 0 Day 1, Day 7 prior to breakfast, Hour 0 Day 14 for all cohorts; Days 21 and 28 for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Lipid Parameters (mg/dL) by Treatment Group on Days 14 and 28 - Part B</measure>
    <time_frame>Days 0,14 and 28</time_frame>
    <description>Blood samples (3.5 mL) for all lipids and 2 mL for ApoB100 were collected at Hour 0 Day 1, Day 7 prior to breakfast, Hour 0 Day 14 for all cohorts; Days 21 and 28 for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">117</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>PF-06291874</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06291874</intervention_name>
    <description>The dosing schedule is 5, 15, 50, 100 and 150 mg QD for 14 days for the first 5 cohorts in Part A. The dosing schedule for the first cohort in Part B is 15 mg QD for 14 days and 30 mg QD for 28 days</description>
    <arm_group_label>PF-06291874</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets will be administered QD in each of the cohorts for 14 days (Part A cohorts 1- 5 and Part B cohort 1) or 28 days (Part B cohort 2).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and female subjects of non-childbearing potential between the ages of 18 and 70
             years, inclusive of age at the time of the screening visit.

        Female subjects of non-childbearing potential must meet at least one of the following
        criteria:

          1. Achieved postmenopausal status, defined as: cessation of regular menses for at least
             12 consecutive months with no alternative pathological or physiological cause; and
             have a serum FSH level within the laboratory's reference range for postmenopausal
             females;

          2. Have undergone a documented hysterectomy and/or bilateral oophorectomy;

          3. Have medically confirmed ovarian failure.

          4. All other female subjects (including females with tubal ligations and females that do
             NOT have a documented hysterectomy, bilateral oophorectomy and/or ovarian failure)
             will be considered to be of childbearing potential.

               -  Body Mass Index (BMI) of 18.0 to 45.0 kg/m2; and a total body weight &gt;50 kg (110
                  lbs).

               -  An informed consent document signed and dated by the subject.

               -  Subjects who are willing and able to comply with scheduled visits, treatment
                  plan, laboratory tests, and other study procedures.

        PART A ONLY: Subjects treated with metformin monotherapy for at least 3 months at the time
        of the screening visit; and have been on a stable dose of metformin for at least 6 weeks
        prior to the first dose of study drug on Day 1. Subjects must be taking a minimum total
        metformin daily dose of least 1000 mg. Subjects treated with a dipeptidyl peptidase-4
        inhibitor (DPP-4i), a sulfonylurea or a sodium-glucose cotransporter-2 inhibitor (SGLT-2i)
        in combination with metformin may be eligible if washed off the DPP-4i, sulfonylurea or
        SGLT-2i for a minimum of 4 weeks prior to dosing. Subjects being washed off a DPP-4i,
        sulfonylurea or SGLT-2i will still need to meet the fasting glucose requirements as defined
        in the Inclusion Criteria.

        PART B ONLY: Subjects treated with metformin plus a sulfonylurea for at least 3 months at
        the time of the screening visit; and have been on a stable dose of metformin and a
        sulfonylurea for at least 6 weeks prior to first dose of study drug on Day 1. Subjects must
        be taking a minimum total metformin daily dose of least 1000 mg and a total daily dose of
        sulfonylurea that is at least the minimum recommended starting dose found in the product
        label. Subjects treated with a DPP-4i or SGLT-2i in combination with metformin and a
        sulfonylurea may be eligible if washed off the DPP-4i or SGLT-2i for a minimum of 4 weeks
        before dosing.

        Exclusion Criteria:

          -  History of Type 1 diabetes mellitus or secondary forms of diabetes.

          -  One or more self-reported hypoglycemic episodes of severe intensity within 3 months of
             screening; or two or more self-reported hypoglycemic episodes of severe intensity
             within the last 6 months.

          -  Recent [ie, within six (6) months prior to screening] evidence or medical history of
             unstable concurrent disease such as: clinically significant hematological,
             endocrine,pulmonary, gastrointestinal (including severe gastroparesis),
             cardiovascular, hepatic, psychiatric, neurologic, or clinically significant allergic
             disease (excluding treated and untreated seasonal allergies at time of dosing).
             Subjects who have chronic conditions other than T2DM (for example,
             hypercholesterolemia or hypertension) but are controlled by either diet or stable (for
             the last 4 weeks prior to screening) doses of medications may be included as well (for
             example, a subject with hypercholesterolemia on appropriate treatment is eligible).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anaheim Clinical Trials</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Profil Institute for Clinical Research, Inc.</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MRA Clinical Research, LLC</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B4801003&amp;StudyName=PF-06291874%20Multiple%20Ascending%20Dose%20Study%20In%20Type%202%20Diabetes%20Mellitus%20Patients</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>May 14, 2013</study_first_submitted>
  <study_first_submitted_qc>May 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2013</study_first_posted>
  <results_first_submitted>July 5, 2017</results_first_submitted>
  <results_first_submitted_qc>February 28, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 1, 2018</results_first_posted>
  <last_update_submitted>February 28, 2018</last_update_submitted>
  <last_update_submitted_qc>February 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Part A: Placebo</title>
          <description>Participants received placebo matched to PF-06291874 orally once daily for 14 or 28 days</description>
        </group>
        <group group_id="P2">
          <title>Part A: PF-06291874 5 mg</title>
          <description>Participants received PF-06291874 5 milligram (mg) orally once daily for 14 days</description>
        </group>
        <group group_id="P3">
          <title>Part A: PF-06291874 15 mg</title>
          <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
        </group>
        <group group_id="P4">
          <title>Part A: PF-06291874 50 mg</title>
          <description>Participants received PF-06291874 50 mg orally once daily for 14 days</description>
        </group>
        <group group_id="P5">
          <title>Part A: PF-06291874 100 mg</title>
          <description>Participants received PF-06291874 100 mg orally once daily for 28 days</description>
        </group>
        <group group_id="P6">
          <title>Part A: PF-06291874 150 mg</title>
          <description>Participants received PF-06291874 150 mg orally once daily for 14 days</description>
        </group>
        <group group_id="P7">
          <title>Part B: Placebo</title>
          <description>Participants received placebo matched to PF-06291874 orally once daily for 14 or 28 days</description>
        </group>
        <group group_id="P8">
          <title>Part B: PF-06291874 15 mg</title>
          <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
        </group>
        <group group_id="P9">
          <title>Part B: PF-06291874 30 mg</title>
          <description>Participants received PF-06291874 30 mg orally once daily for 28 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="14"/>
                <participants group_id="P6" count="12"/>
                <participants group_id="P7" count="13"/>
                <participants group_id="P8" count="10"/>
                <participants group_id="P9" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="14"/>
                <participants group_id="P6" count="12"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="10"/>
                <participants group_id="P9" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Part A: Placebo</title>
          <description>Participants received placebo matched to PF-06291874 orally once daily for 14 or 28 days</description>
        </group>
        <group group_id="B2">
          <title>Part A: PF-06291874 5 mg</title>
          <description>Participants received PF-06291874 5 milligram (mg) orally once daily for 14 days</description>
        </group>
        <group group_id="B3">
          <title>Part A: PF-06291874 15 mg</title>
          <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
        </group>
        <group group_id="B4">
          <title>Part A: PF-06291874 50 mg</title>
          <description>Participants received PF-06291874 50 mg orally once daily for 14 days</description>
        </group>
        <group group_id="B5">
          <title>Part A: PF-06291874 100 mg</title>
          <description>Participants received PF-06291874 100 mg orally once daily for 28 days</description>
        </group>
        <group group_id="B6">
          <title>Part A: PF-06291874 150 mg</title>
          <description>Participants received PF-06291874 150 mg orally once daily for 14 days</description>
        </group>
        <group group_id="B7">
          <title>Part B: Placebo</title>
          <description>Participants received placebo matched to PF-06291874 orally once daily for 14 or 28 days</description>
        </group>
        <group group_id="B8">
          <title>Part B: PF-06291874 15 mg</title>
          <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
        </group>
        <group group_id="B9">
          <title>Part B: PF-06291874 30 mg</title>
          <description>Participants received PF-06291874 30 mg orally once daily for 28 days</description>
        </group>
        <group group_id="B10">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="12"/>
            <count group_id="B5" value="14"/>
            <count group_id="B6" value="12"/>
            <count group_id="B7" value="13"/>
            <count group_id="B8" value="10"/>
            <count group_id="B9" value="14"/>
            <count group_id="B10" value="117"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.9" spread="5.1"/>
                    <measurement group_id="B2" value="58.9" spread="5"/>
                    <measurement group_id="B3" value="53.8" spread="5.9"/>
                    <measurement group_id="B4" value="56.2" spread="7.7"/>
                    <measurement group_id="B5" value="54" spread="10.8"/>
                    <measurement group_id="B6" value="56.1" spread="6.7"/>
                    <measurement group_id="B7" value="56.3" spread="7.6"/>
                    <measurement group_id="B8" value="54.2" spread="8.7"/>
                    <measurement group_id="B9" value="55" spread="10"/>
                    <measurement group_id="B10" value="56.1" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="9"/>
                    <measurement group_id="B8" value="7"/>
                    <measurement group_id="B9" value="12"/>
                    <measurement group_id="B10" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Had Protocol-Defined Total Hypoglycemic Adverse Event (HAE) - Part A</title>
        <description>A hypoglycemic event (HAE) was identified by characteristic symptoms or blood glucose levels. Hypoglycaemia was assessed and reported in several categories: severe hypoglycaemia, documented symptomatic hypoglycaemia, asymptomatic hypoglycaemia, and probable hypoglycaemia.</description>
        <time_frame>Day 1 up to 7-11 days after last dose of study drug</time_frame>
        <population>The Safety Analysis Set was defined as all participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 14 or 28 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 5 mg</title>
            <description>Participants received PF-06291874 5 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PF-06291874 15 mg</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O4">
            <title>PF-06291874 50 mg</title>
            <description>Participants received PF-06291874 50 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O5">
            <title>PF-06291874 100 mg</title>
            <description>Participants received PF-06291874 100 mg orally once daily for 28 days</description>
          </group>
          <group group_id="O6">
            <title>PF-06291874 150 mg</title>
            <description>Participants received PF-06291874 150 mg orally once daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Had Protocol-Defined Total Hypoglycemic Adverse Event (HAE) - Part A</title>
          <description>A hypoglycemic event (HAE) was identified by characteristic symptoms or blood glucose levels. Hypoglycaemia was assessed and reported in several categories: severe hypoglycaemia, documented symptomatic hypoglycaemia, asymptomatic hypoglycaemia, and probable hypoglycaemia.</description>
          <population>The Safety Analysis Set was defined as all participants who received at least 1 dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Had Protocol-Defined Total Hypoglycemic Adverse Event (HAE) - Part B</title>
        <description>A hypoglycemic event (HAE) was identified by characteristic symptoms or blood glucose levels. Hypoglycaemia was assessed and reported in several categories: severe hypoglycaemia, documented symptomatic hypoglycaemia, asymptomatic hypoglycaemia, and probable hypoglycaemia.</description>
        <time_frame>Day 1 up to 7-11 days after last dose of study drug</time_frame>
        <population>The Safety Analysis Set was defined as all participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 14 or 28 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 15 mg</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PF-06291874 30 mg</title>
            <description>Participants received PF-06291874 30 mg orally once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Had Protocol-Defined Total Hypoglycemic Adverse Event (HAE) - Part B</title>
          <description>A hypoglycemic event (HAE) was identified by characteristic symptoms or blood glucose levels. Hypoglycaemia was assessed and reported in several categories: severe hypoglycaemia, documented symptomatic hypoglycaemia, asymptomatic hypoglycaemia, and probable hypoglycaemia.</description>
          <population>The Safety Analysis Set was defined as all participants who received at least 1 dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Electrocardiograms (ECGs) Data Met Criteria of Potential Clinical Concern - Part A</title>
        <description>ECG criteria of potential clinical concern were 1), PR interval: greater than or equal to (&gt;=)300 milliseconds (msec); &gt;=25 percent (%) increase when baselinegreater than (&gt;)200 msec; or increase &gt;=50% when baseline less than or equal to (&lt;=)200 msec; 2), QRS interval: &gt;=140 msec; &gt;=50% increase from baseline; 3), QT interval: &gt;=500 msec, QTc interval using cridericia's formula (QTcF interval): absolute value &gt;=450 - &lt;480 msec, &gt;=480-&lt;500 msec, &gt;500 msec; absolute change 30 - &lt;60, &gt;=60 msec.</description>
        <time_frame>Predose (0),4,6,8,12,24 hours on Days 1 and 14; 8 hours post dose on Days 3,7,11 for all Cohorts ; predose on Day 17 for Cohorts 1- 4A and 1B; predose on Days 21 and 28 for Cohorts 5A and 2B.</time_frame>
        <population>The Safety Analysis Set was defined as all participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 14 or 28 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 5 mg</title>
            <description>Participants received PF-06291874 5 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PF-06291874 15 mg</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O4">
            <title>PF-06291874 50 mg</title>
            <description>Participants received PF-06291874 50 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O5">
            <title>PF-06291874 100 mg</title>
            <description>Participants received PF-06291874 100 mg orally once daily for 28 days</description>
          </group>
          <group group_id="O6">
            <title>PF-06291874 150 mg</title>
            <description>Participants received PF-06291874 150 mg orally once daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Electrocardiograms (ECGs) Data Met Criteria of Potential Clinical Concern - Part A</title>
          <description>ECG criteria of potential clinical concern were 1), PR interval: greater than or equal to (&gt;=)300 milliseconds (msec); &gt;=25 percent (%) increase when baselinegreater than (&gt;)200 msec; or increase &gt;=50% when baseline less than or equal to (&lt;=)200 msec; 2), QRS interval: &gt;=140 msec; &gt;=50% increase from baseline; 3), QT interval: &gt;=500 msec, QTc interval using cridericia's formula (QTcF interval): absolute value &gt;=450 - &lt;480 msec, &gt;=480-&lt;500 msec, &gt;500 msec; absolute change 30 - &lt;60, &gt;=60 msec.</description>
          <population>The Safety Analysis Set was defined as all participants who received at least 1 dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PR interval &gt;=300 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS interval &gt;=140 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT interval &gt;=500 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval 450-480 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval 480-500 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval &gt;=500 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR interval increase ≥25%/50%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS interval increase &gt;=50%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF increase 30-60 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF increase &gt;=60 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With ECGs Data Met Criteria of Potential Clinical Concern - Part B</title>
        <description>ECG criteria of potential clinical concern were 1), PR interval: &gt;=300 msec; &gt;=25% increase when baseline &gt;200 msec; or increase &gt;=50% when baseline &lt;=200 msec; 2), QRS interval: &gt;=140 msec; &gt;=50% increase from baseline; 3), QT interval: &gt;=500 msec, QTcF interval: absolute value &gt;=450 - &lt;480 msec, &gt;=480-&lt;500 msec, &gt;500 msec; absolute change 30 - &lt;60, &gt;=60 msec.</description>
        <time_frame>Predose (0),4,6,8,12,24 hours on Days 1 and 14; 8 hours post dose on Days 3,7,11 for all Cohorts ; predose on Day 17 for Cohorts 1- 4A and 1B; predose on Days 21 and 28 for Cohorts 5A and 2B.</time_frame>
        <population>The Safety Analysis Set was defined as all participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 14 or 28 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 15 mg</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PF-06291874 30 mg</title>
            <description>Participants received PF-06291874 30 mg orally once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With ECGs Data Met Criteria of Potential Clinical Concern - Part B</title>
          <description>ECG criteria of potential clinical concern were 1), PR interval: &gt;=300 msec; &gt;=25% increase when baseline &gt;200 msec; or increase &gt;=50% when baseline &lt;=200 msec; 2), QRS interval: &gt;=140 msec; &gt;=50% increase from baseline; 3), QT interval: &gt;=500 msec, QTcF interval: absolute value &gt;=450 - &lt;480 msec, &gt;=480-&lt;500 msec, &gt;500 msec; absolute change 30 - &lt;60, &gt;=60 msec.</description>
          <population>The Safety Analysis Set was defined as all participants who received at least 1 dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PR interval &gt;=300 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS interval &gt;=140 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT interval &gt;=500 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval 450-480 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval 480-500 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval &gt;=500 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR interval increase ≥25%/50%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS interval increase &gt;=50%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF increase 30-60 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF increase &gt;=60 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Vital Signs Data Met Criteria of Potential Clinical Concern - Part A</title>
        <description>Vital signs included blood pressure (BP; supine, sitting and standing) and pulse rate. Vital signs criteria of potential clinical concern were 1), BP: systolic BP (SBP) greater than or equal to (&gt;=) 30 millimeters of mercury (mm Hg) change from grand baseline in same posture, systolic less than (&lt;) 90 mm Hg; diastolic BP (DBP) &gt;=20 mm Hg change from grand baseline in same posture, diastolic &lt;50 mm Hg; 2), pulse rate (supine): &lt;40 or greater than (&gt;) 120 beats per minute (bpm).</description>
        <time_frame>Predose (0),4,6,8,12,24 hours on Days 1 and 14; 8 hours post dose on Days 3,7,11 for all Cohorts ; predose on Day 17 for Cohorts 1- 4A and 1B; predose on Days 21 and 28 for Cohorts 5A and 2B.</time_frame>
        <population>The Safety Analysis Set was defined as all participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 14 or 28 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 5 mg</title>
            <description>Participants received PF-06291874 5 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PF-06291874 15 mg</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O4">
            <title>PF-06291874 50 mg</title>
            <description>Participants received PF-06291874 50 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O5">
            <title>PF-06291874 100 mg</title>
            <description>Participants received PF-06291874 100 mg orally once daily for 28 days</description>
          </group>
          <group group_id="O6">
            <title>PF-06291874 150 mg</title>
            <description>Participants received PF-06291874 150 mg orally once daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Vital Signs Data Met Criteria of Potential Clinical Concern - Part A</title>
          <description>Vital signs included blood pressure (BP; supine, sitting and standing) and pulse rate. Vital signs criteria of potential clinical concern were 1), BP: systolic BP (SBP) greater than or equal to (&gt;=) 30 millimeters of mercury (mm Hg) change from grand baseline in same posture, systolic less than (&lt;) 90 mm Hg; diastolic BP (DBP) &gt;=20 mm Hg change from grand baseline in same posture, diastolic &lt;50 mm Hg; 2), pulse rate (supine): &lt;40 or greater than (&gt;) 120 beats per minute (bpm).</description>
          <population>The Safety Analysis Set was defined as all participants who received at least 1 dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Supine SBP &lt;90 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine DBP &lt;50 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine pulse rate &lt;40 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase:supine SBP≥30 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase:supine DBP≥20 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decrease:supine SBP≥30 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decrease:supine DBP≥20 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine pulse rate &gt;120 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Vital Signs Data Met Criteria of Potential Clinical Concern - Part B</title>
        <description>Vital signs included blood pressure (BP; supine, sitting and standing) and pulse rate. Vital signs criteria of potential clinical concern were 1), BP: SBP &gt;= 30 mm Hg change from grand baseline in same posture, SBP &lt; 90 mm Hg; DBP &gt;=20 mm Hg change from grand baseline in same posture, DBP&lt;50 mm Hg; 2), pulse rate (supine): &lt;40 or &gt; 120 bpm.</description>
        <time_frame>Predose (0),4,6,8,12,24 hours on Days 1 and 14; 8 hours post dose on Days 3,7,11 for all Cohorts ; predose on Day 17 for Cohorts 1- 4A and 1B; predose on Days 21 and 28 for Cohorts 5A and 2B.</time_frame>
        <population>The Safety Analysis Set was defined as all participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 14 or 28 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 15 mg</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PF-06291874 30 mg</title>
            <description>Participants received PF-06291874 30 mg orally once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Vital Signs Data Met Criteria of Potential Clinical Concern - Part B</title>
          <description>Vital signs included blood pressure (BP; supine, sitting and standing) and pulse rate. Vital signs criteria of potential clinical concern were 1), BP: SBP &gt;= 30 mm Hg change from grand baseline in same posture, SBP &lt; 90 mm Hg; DBP &gt;=20 mm Hg change from grand baseline in same posture, DBP&lt;50 mm Hg; 2), pulse rate (supine): &lt;40 or &gt; 120 bpm.</description>
          <population>The Safety Analysis Set was defined as all participants who received at least 1 dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Supine SBP &lt;90 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine DBP &lt;50 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine pulse rate &lt;40 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase:supine SBP≥30 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decrease:supine SBP≥30 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decrease:supine DBP≥20 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine pulse rate &gt;120 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase:supine DBP≥20 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Any Abnormal Laboratory Test Results - Part A</title>
        <description>The laboratory test included: hematology (hemoglobin, hematocrit, red blood cell count, MCV, MCH, MCHC, platelets, white blood cell count, absolute lymphocytes, absolute total neutrophils, absolute basophils, absolute eosinophils and absolute monocytes), coagulation (PPT, prothrombin), liver function(total bilirubin, AST, ALT, alkaline phosphatase, total protein and albumin), renal function (blood urea nitrogen, creatinine, uric acid), Lipids (cholesterol, HDL cholesterol, LDL cholesterol, triglycerides), Electrolytes (sodium, potassium, chloride, calcium, venous bicarbonate), clinical chemistry (glucose, glycosylated, hemoglobin, amylase, lipase), urinalysis dipstick (urine PH, urine glucose, urine ketones, urine protein, urine urobilinogen, urine bilirubin, urine nitrite, urine leukocyte, esterase), urinalysis microscopy (urine RBC, urine WBC, urine bacteria). Laboratory abnormality was determined by the investigator based on pre-defined criteria.</description>
        <time_frame>Predose on Days 0,3,7,11 for all cohorts and 14 and 17 for Cohorts 1- 4A and 1B, and pre-dose on Days 21 and 28 for Cohorts 5A and 2B.</time_frame>
        <population>The Safety Analysis Set was defined as all participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 14 or 28 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 5 mg</title>
            <description>Participants received PF-06291874 5 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PF-06291874 15 mg</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O4">
            <title>PF-06291874 50 mg</title>
            <description>Participants received PF-06291874 50 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O5">
            <title>PF-06291874 100 mg</title>
            <description>Participants received PF-06291874 100 mg orally once daily for 28 days</description>
          </group>
          <group group_id="O6">
            <title>PF-06291874 150 mg</title>
            <description>Participants received PF-06291874 150 mg orally once daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Abnormal Laboratory Test Results - Part A</title>
          <description>The laboratory test included: hematology (hemoglobin, hematocrit, red blood cell count, MCV, MCH, MCHC, platelets, white blood cell count, absolute lymphocytes, absolute total neutrophils, absolute basophils, absolute eosinophils and absolute monocytes), coagulation (PPT, prothrombin), liver function(total bilirubin, AST, ALT, alkaline phosphatase, total protein and albumin), renal function (blood urea nitrogen, creatinine, uric acid), Lipids (cholesterol, HDL cholesterol, LDL cholesterol, triglycerides), Electrolytes (sodium, potassium, chloride, calcium, venous bicarbonate), clinical chemistry (glucose, glycosylated, hemoglobin, amylase, lipase), urinalysis dipstick (urine PH, urine glucose, urine ketones, urine protein, urine urobilinogen, urine bilirubin, urine nitrite, urine leukocyte, esterase), urinalysis microscopy (urine RBC, urine WBC, urine bacteria). Laboratory abnormality was determined by the investigator based on pre-defined criteria.</description>
          <population>The Safety Analysis Set was defined as all participants who received at least 1 dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Any Abnormal Laboratory Test Results - Part B</title>
        <description>The laboratory test included: hematology (hemoglobin, hematocrit, red blood cell count, MCV, MCH, MCHC, platelets, white blood cell count, absolute lymphocytes, absolute total neutrophils, absolute basophils, absolute eosinophils and absolute monocytes), coagulation (PPT, prothrombin), liver function(total bilirubin, AST, ALT, alkaline phosphatase, total protein and albumin), renal function (blood urea nitrogen, creatinine, uric acid), Lipids (cholesterol, HDL cholesterol, LDL cholesterol, triglycerides), Electrolytes (sodium, potassium, chloride, calcium, venous bicarbonate), clinical chemistry (glucose, glycosylated, hemoglobin, amylase, lipase), urinalysis dipstick (urine PH, urine glucose, urine ketones, urine protein, urine urobilinogen, urine bilirubin, urine nitrite, urine leukocyte, esterase), urinalysis microscopy (urine RBC, urine WBC, urine bacteria). Laboratory abnormality was determined by the investigator based on pre-defined criteria.</description>
        <time_frame>Predose on Days 0,3,7,11 for all cohorts and 14 and 17 for Cohorts 1- 4A and 1B, and pre-dose on Days 21 and 28 for Cohorts 5A and 2B.</time_frame>
        <population>The Safety Analysis Set was defined as all participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06291874 5 mg</title>
            <description>Participants received PF-06291874 5 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 30 mg</title>
            <description>Participants received PF-06291874 30 mg orally once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 14 or 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Abnormal Laboratory Test Results - Part B</title>
          <description>The laboratory test included: hematology (hemoglobin, hematocrit, red blood cell count, MCV, MCH, MCHC, platelets, white blood cell count, absolute lymphocytes, absolute total neutrophils, absolute basophils, absolute eosinophils and absolute monocytes), coagulation (PPT, prothrombin), liver function(total bilirubin, AST, ALT, alkaline phosphatase, total protein and albumin), renal function (blood urea nitrogen, creatinine, uric acid), Lipids (cholesterol, HDL cholesterol, LDL cholesterol, triglycerides), Electrolytes (sodium, potassium, chloride, calcium, venous bicarbonate), clinical chemistry (glucose, glycosylated, hemoglobin, amylase, lipase), urinalysis dipstick (urine PH, urine glucose, urine ketones, urine protein, urine urobilinogen, urine bilirubin, urine nitrite, urine leukocyte, esterase), urinalysis microscopy (urine RBC, urine WBC, urine bacteria). Laboratory abnormality was determined by the investigator based on pre-defined criteria.</description>
          <population>The Safety Analysis Set was defined as all participants who received at least 1 dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Single Dose Maximum Plasma Concentration (Cmax) for PF-06291874 - Part A</title>
        <description>Cmax was maximum plasma concentration. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for pharmacokinetic (PK) analysis were collected at 0, 2, 4, 6, 8, 12, 19 and 24 hours post dose.</description>
        <time_frame>0 hour (pre-dose), 2, 4, 6, 8, 12, 19, 24 hours post-dose on Day 1</time_frame>
        <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who had at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06291874 5 mg</title>
            <description>Participants received PF-06291874 5 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 15 mg</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PF-06291874 50 mg</title>
            <description>Participants received PF-06291874 50 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O4">
            <title>PF-06291874 100 mg</title>
            <description>Participants received PF-06291874 100 mg orally once daily for 28 days</description>
          </group>
          <group group_id="O5">
            <title>PF-06291874 150 mg</title>
            <description>Participants received PF-06291874 150 mg orally once daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Single Dose Maximum Plasma Concentration (Cmax) for PF-06291874 - Part A</title>
          <description>Cmax was maximum plasma concentration. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for pharmacokinetic (PK) analysis were collected at 0, 2, 4, 6, 8, 12, 19 and 24 hours post dose.</description>
          <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who had at least 1 of the PK parameters of interest.</population>
          <units>nanograms per milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137.0" spread="17"/>
                    <measurement group_id="O2" value="427.1" spread="22"/>
                    <measurement group_id="O3" value="1308" spread="26"/>
                    <measurement group_id="O4" value="2582" spread="19"/>
                    <measurement group_id="O5" value="3288" spread="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Single Dose Normalized Cmax (Cmax[dn]) for PF-06291874 - Part A</title>
        <description>Cmax (dn) was dose normalized maximum plasma concentration. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for pharmacokinetic (PK) analysis were collected at 0, 2, 4, 6, 8, 12, 19 and 24 hours post dose.</description>
        <time_frame>0 hour (pre-dose), 2, 4, 6, 8, 12, 19, 24 hours post-dose on Day 1</time_frame>
        <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who had at least 1 of the PK parameters of interest</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06291874 5 mg</title>
            <description>Participants received PF-06291874 5 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 15 mg</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PF-06291874 50 mg</title>
            <description>Participants received PF-06291874 50 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O4">
            <title>PF-06291874 100 mg</title>
            <description>Participants received PF-06291874 100 mg orally once daily for 28 days</description>
          </group>
          <group group_id="O5">
            <title>PF-06291874 150 mg</title>
            <description>Participants received PF-06291874 150 mg orally once daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Single Dose Normalized Cmax (Cmax[dn]) for PF-06291874 - Part A</title>
          <description>Cmax (dn) was dose normalized maximum plasma concentration. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for pharmacokinetic (PK) analysis were collected at 0, 2, 4, 6, 8, 12, 19 and 24 hours post dose.</description>
          <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who had at least 1 of the PK parameters of interest</population>
          <units>ng/mL/mg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.40" spread="17"/>
                    <measurement group_id="O2" value="28.46" spread="22"/>
                    <measurement group_id="O3" value="26.15" spread="26"/>
                    <measurement group_id="O4" value="25.82" spread="19"/>
                    <measurement group_id="O5" value="21.90" spread="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Single Dose Cmax for PF-06291874 - Part B</title>
        <description>Cmax was maximum plasma concentration. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19 and 24 hours post dose.</description>
        <time_frame>0 hour (pre-dose), 2, 4, 6, 8, 12, 19, 24 hours post-dose on Day 1</time_frame>
        <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who had at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06291874 15 mg</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 30 mg</title>
            <description>Participants received PF-06291874 30 mg orally once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Single Dose Cmax for PF-06291874 - Part B</title>
          <description>Cmax was maximum plasma concentration. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19 and 24 hours post dose.</description>
          <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who had at least 1 of the PK parameters of interest.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="373.6" spread="16"/>
                    <measurement group_id="O2" value="687.6" spread="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Single Dose Normalized Cmax (Cmax[dn]) for PF-06291874 - Part B</title>
        <description>Cmax (dn) was dose normalized maximum plasma concentration. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19 and 24 hours post dose</description>
        <time_frame>0 hour (pre-dose), 2, 4, 6, 8, 12, 19, 24 hours post-dose on Day 1</time_frame>
        <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who had at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06291874 15 mg</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 30 mg</title>
            <description>Participants received PF-06291874 30 mg orally once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Single Dose Normalized Cmax (Cmax[dn]) for PF-06291874 - Part B</title>
          <description>Cmax (dn) was dose normalized maximum plasma concentration. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19 and 24 hours post dose</description>
          <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who had at least 1 of the PK parameters of interest.</population>
          <units>ng/mL/mg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.90" spread="16"/>
                    <measurement group_id="O2" value="22.92" spread="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Single Dose Time at Which Cmax Occurred (Tmax) for PF-06291874 - Part A</title>
        <description>Tmax was time at which Cmax occurred. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
        <time_frame>0 hour (pre-dose), 2, 4, 6, 8, 12, 19, 24 hours post-dose on Day 1</time_frame>
        <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who had at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06291874 5 mg</title>
            <description>Participants received PF-06291874 5 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 15 mg</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PF-06291874 50 mg</title>
            <description>Participants received PF-06291874 50 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O4">
            <title>PF-06291874 100 mg</title>
            <description>Participants received PF-06291874 100 mg orally once daily for 28 days</description>
          </group>
          <group group_id="O5">
            <title>PF-06291874 150 mg</title>
            <description>Participants received PF-06291874 150 mg orally once daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Single Dose Time at Which Cmax Occurred (Tmax) for PF-06291874 - Part A</title>
          <description>Tmax was time at which Cmax occurred. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
          <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who had at least 1 of the PK parameters of interest.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.00" spread="17" lower_limit="2.00" upper_limit="8.03"/>
                    <measurement group_id="O2" value="5.00" spread="22" lower_limit="4.00" upper_limit="12.0"/>
                    <measurement group_id="O3" value="6.00" spread="26" lower_limit="2.00" upper_limit="8.02"/>
                    <measurement group_id="O4" value="6.07" spread="19" lower_limit="4.00" upper_limit="8.00"/>
                    <measurement group_id="O5" value="4.00" spread="32" lower_limit="2.00" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Single Dose Tmax for PF-06291874 - Part B</title>
        <description>Tmax was time at which Cmax occurred. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
        <time_frame>0 hour (pre-dose), 2, 4, 6, 8, 12, 19, 24 hours post-dose on Day 1</time_frame>
        <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who had at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06291874 15 mg</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 30 mg</title>
            <description>Participants received PF-06291874 30 mg orally once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Single Dose Tmax for PF-06291874 - Part B</title>
          <description>Tmax was time at which Cmax occurred. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
          <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who had at least 1 of the PK parameters of interest.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.02" spread="16" lower_limit="4.00" upper_limit="12.0"/>
                    <measurement group_id="O2" value="6.00" spread="34" lower_limit="2.00" upper_limit="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Single Dose AUCtau (Area Under the Concentration-time Profile From Time Zero to Time Tau, the Dosing Interval, Where Tau = 24 Hours) for PF-06291874 - Part A</title>
        <description>AUCtau was area under the concentration-time profile from time zero to time tau, the dosing interval, where tau = 24 hours. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
        <time_frame>0 hour (pre-dose), 2, 4, 6, 8, 12, 19, 24 hours post-dose on Day 1</time_frame>
        <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who had at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06291874 5 mg</title>
            <description>Participants received PF-06291874 5 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 15 mg</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PF-06291874 50 mg</title>
            <description>Participants received PF-06291874 50 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O4">
            <title>PF-06291874 100 mg</title>
            <description>Participants received PF-06291874 100 mg orally once daily for 28 days</description>
          </group>
          <group group_id="O5">
            <title>PF-06291874 150 mg</title>
            <description>Participants received PF-06291874 150 mg orally once daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Single Dose AUCtau (Area Under the Concentration-time Profile From Time Zero to Time Tau, the Dosing Interval, Where Tau = 24 Hours) for PF-06291874 - Part A</title>
          <description>AUCtau was area under the concentration-time profile from time zero to time tau, the dosing interval, where tau = 24 hours. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
          <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who had at least 1 of the PK parameters of interest.</population>
          <units>ng.hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2181" spread="27" lower_limit="2.00" upper_limit="8.03"/>
                    <measurement group_id="O2" value="6821" spread="20" lower_limit="4.00" upper_limit="12.0"/>
                    <measurement group_id="O3" value="20650" spread="27" lower_limit="2.00" upper_limit="8.02"/>
                    <measurement group_id="O4" value="43040" spread="20" lower_limit="4.00" upper_limit="8.00"/>
                    <measurement group_id="O5" value="51860" spread="34" lower_limit="2.00" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Single Dose AUCtau for PF-06291874 - Part B</title>
        <description>AUCtau was area under the concentration-time profile from time zero to time tau, the dosing interval, where tau = 24 hours. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
        <time_frame>0 hour (pre-dose), 2, 4, 6, 8, 12, 19, 24 hours post-dose on Day 1</time_frame>
        <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who had at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06291874 15 mg</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 30 mg</title>
            <description>Participants received PF-06291874 30 mg orally once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Single Dose AUCtau for PF-06291874 - Part B</title>
          <description>AUCtau was area under the concentration-time profile from time zero to time tau, the dosing interval, where tau = 24 hours. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
          <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who had at least 1 of the PK parameters of interest.</population>
          <units>ng.hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6486" spread="14" lower_limit="4.00" upper_limit="12.0"/>
                    <measurement group_id="O2" value="11280" spread="35" lower_limit="2.00" upper_limit="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Multiple Dose Cmax for PF-06291874 - Part A</title>
        <description>Cmax was maximum plasma concentration. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
        <time_frame>Predose (0), 2, 4, 6, 8, 12, 19, 24 hours post dose on Day 14</time_frame>
        <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who had at least 1 of the PK parameters of interest. The number of participants analyzed was the number of participants contributing to the summary statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06291874 5 mg</title>
            <description>Participants received PF-06291874 5 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 15 mg</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PF-06291874 50 mg</title>
            <description>Participants received PF-06291874 50 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O4">
            <title>PF-06291874 100 mg</title>
            <description>Participants received PF-06291874 100 mg orally once daily for 28 days</description>
          </group>
          <group group_id="O5">
            <title>PF-06291874 150 mg</title>
            <description>Participants received PF-06291874 150 mg orally once daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Dose Cmax for PF-06291874 - Part A</title>
          <description>Cmax was maximum plasma concentration. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
          <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who had at least 1 of the PK parameters of interest. The number of participants analyzed was the number of participants contributing to the summary statistics.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="213.4" spread="27"/>
                    <measurement group_id="O2" value="669.1" spread="17"/>
                    <measurement group_id="O3" value="2220" spread="31"/>
                    <measurement group_id="O4" value="4362" spread="30"/>
                    <measurement group_id="O5" value="5957" spread="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Multiple Dose Cmax for PF-06291874 - Part B</title>
        <description>Cmax was maximum plasma concentration. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
        <time_frame>Predose (0), 2, 4, 6, 8, 12, 19, 24 hours post dose on Day 14</time_frame>
        <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who had at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06291874 15 mg</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 30 mg</title>
            <description>Participants received PF-06291874 30 mg orally once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Dose Cmax for PF-06291874 - Part B</title>
          <description>Cmax was maximum plasma concentration. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
          <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who had at least 1 of the PK parameters of interest.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="663.1" spread="19"/>
                    <measurement group_id="O2" value="1108" spread="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Multiple Dose Tmax for PF-06291874 - Part A</title>
        <description>Tmax was time at which Cmax occurred. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
        <time_frame>Predose (0), 2, 4, 6, 8, 12, 19, 24 hours post dose on Day 14</time_frame>
        <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who had at least 1 of the PK parameters of interest. The number of participants analyzed was the number of participants contributing to the summary statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06291874 5 mg</title>
            <description>Participants received PF-06291874 5 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 15 mg</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PF-06291874 50 mg</title>
            <description>Participants received PF-06291874 50 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O4">
            <title>PF-06291874 100 mg</title>
            <description>Participants received PF-06291874 100 mg orally once daily for 28 days</description>
          </group>
          <group group_id="O5">
            <title>PF-06291874 150 mg</title>
            <description>Participants received PF-06291874 150 mg orally once daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Dose Tmax for PF-06291874 - Part A</title>
          <description>Tmax was time at which Cmax occurred. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
          <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who had at least 1 of the PK parameters of interest. The number of participants analyzed was the number of participants contributing to the summary statistics.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.98" lower_limit="4.00" upper_limit="12.0"/>
                    <measurement group_id="O2" value="5.00" lower_limit="4.00" upper_limit="8.00"/>
                    <measurement group_id="O3" value="4.02" lower_limit="2.02" upper_limit="6.00"/>
                    <measurement group_id="O4" value="6.00" lower_limit="2.02" upper_limit="12.0"/>
                    <measurement group_id="O5" value="5.00" lower_limit="1.98" upper_limit="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Multiple Dose Tmax for PF-06291874 - Part B</title>
        <description>Tmax was time at which Cmax occurred. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
        <time_frame>Predose (0), 2, 4, 6, 8, 12, 19, 24 hours post dose on Day 14</time_frame>
        <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who had at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06291874 15 mg</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 30 mg</title>
            <description>Participants received PF-06291874 30 mg orally once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Dose Tmax for PF-06291874 - Part B</title>
          <description>Tmax was time at which Cmax occurred. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
          <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who had at least 1 of the PK parameters of interest.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" spread="19" lower_limit="1.95" upper_limit="6.00"/>
                    <measurement group_id="O2" value="6.00" spread="26" lower_limit="2.02" upper_limit="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Multiple Dose AUCtau for PF-06291874 - Part A</title>
        <description>AUCtau was area under the concentration-time profile from time zero to time tau, the dosing interval, where tau = 24 hours. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
        <time_frame>Predose (0), 2, 4, 6, 8, 12, 19, 24 hours post dose on Day 14</time_frame>
        <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who had at least 1 of the PK parameters of interest. The number of participants analyzed was the number of participants contributing to the summary statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06291874 5 mg</title>
            <description>Participants received PF-06291874 5 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 15 mg</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PF-06291874 50 mg</title>
            <description>Participants received PF-06291874 50 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O4">
            <title>PF-06291874 100 mg</title>
            <description>Participants received PF-06291874 100 mg orally once daily for 28 days</description>
          </group>
          <group group_id="O5">
            <title>PF-06291874 150 mg</title>
            <description>Participants received PF-06291874 150 mg orally once daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Dose AUCtau for PF-06291874 - Part A</title>
          <description>AUCtau was area under the concentration-time profile from time zero to time tau, the dosing interval, where tau = 24 hours. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
          <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who had at least 1 of the PK parameters of interest. The number of participants analyzed was the number of participants contributing to the summary statistics.</population>
          <units>ng.hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3800" spread="42" lower_limit="2.00" upper_limit="8.03"/>
                    <measurement group_id="O2" value="11760" spread="19" lower_limit="4.00" upper_limit="12.0"/>
                    <measurement group_id="O3" value="39560" spread="30" lower_limit="2.00" upper_limit="8.02"/>
                    <measurement group_id="O4" value="79550" spread="32" lower_limit="4.00" upper_limit="8.00"/>
                    <measurement group_id="O5" value="105400" spread="37" lower_limit="2.00" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Multiple Dose AUCtau for PF-06291874 - Part B</title>
        <description>AUCtau was area under the concentration-time profile from time zero to time tau, the dosing interval, where tau = 24 hours. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
        <time_frame>Predose (0), 2, 4, 6, 8, 12, 19, 24 hours post dose on Day 14</time_frame>
        <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who have at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06291874 15 mg</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 30 mg</title>
            <description>Participants received PF-06291874 30 mg orally once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Dose AUCtau for PF-06291874 - Part B</title>
          <description>AUCtau was area under the concentration-time profile from time zero to time tau, the dosing interval, where tau = 24 hours. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
          <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who have at least 1 of the PK parameters of interest.</population>
          <units>ng.hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11530" spread="23" lower_limit="4.00" upper_limit="12.0"/>
                    <measurement group_id="O2" value="19270" spread="34" lower_limit="2.00" upper_limit="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Multiple Dose Half Life for PF-06291874</title>
        <description>Plasma half-life was the time measured for the plasma concentration to decrease by one half. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
        <time_frame>Predose (0), 2, 4, 6, 8, 12, 19, 24 hours post dose on Day 14</time_frame>
        <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who have at least 1 of the PK parameters of interest. The number of participants analyzed was the number of participants contributing to the summary statistics. This parameter was not calculated for group: 100 mg Part A, 30 mg Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06291874 5 mg</title>
            <description>Participants received PF-06291874 5 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 15 mg</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PF-06291874 50 mg</title>
            <description>Participants received PF-06291874 50 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O4">
            <title>PF-06291874 150 mg</title>
            <description>Participants received PF-06291874 150 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O5">
            <title>PF-06291874 15 mg - Part B</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Dose Half Life for PF-06291874</title>
          <description>Plasma half-life was the time measured for the plasma concentration to decrease by one half. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
          <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who have at least 1 of the PK parameters of interest. The number of participants analyzed was the number of participants contributing to the summary statistics. This parameter was not calculated for group: 100 mg Part A, 30 mg Part B.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.96" spread="5.6029" lower_limit="2.00" upper_limit="8.03"/>
                    <measurement group_id="O2" value="19.68" spread="4.2407" lower_limit="4.00" upper_limit="12.0"/>
                    <measurement group_id="O3" value="22.24" spread="3.2605" lower_limit="2.00" upper_limit="8.02"/>
                    <measurement group_id="O4" value="20.83" spread="4.1134" lower_limit="2.00" upper_limit="8.00"/>
                    <measurement group_id="O5" value="22.74" spread="3.4699"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Multiple Dose Cmin (Lowest Plasma Concentration Observed During the Dosing Interval) for PF-06291874 - Part A</title>
        <description>Cmin was the lowest plasma concentration observed during the dosing interval. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
        <time_frame>Predose (0), 2, 4, 6, 8, 12, 19, 24 hours post dose on Day 14</time_frame>
        <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who have at least 1 of the PK parameters of interest. The number of participants analyzed was the number of participants contributing to the summary statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06291874 5 mg</title>
            <description>Participants received PF-06291874 5 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 15 mg</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PF-06291874 50 mg</title>
            <description>Participants received PF-06291874 50 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O4">
            <title>PF-06291874 100 mg</title>
            <description>Participants received PF-06291874 100 mg orally once daily for 28 days</description>
          </group>
          <group group_id="O5">
            <title>PF-06291874 150 mg</title>
            <description>Participants received PF-06291874 150 mg orally once daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Dose Cmin (Lowest Plasma Concentration Observed During the Dosing Interval) for PF-06291874 - Part A</title>
          <description>Cmin was the lowest plasma concentration observed during the dosing interval. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
          <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who have at least 1 of the PK parameters of interest. The number of participants analyzed was the number of participants contributing to the summary statistics.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.8" spread="58"/>
                    <measurement group_id="O2" value="350.5" spread="28"/>
                    <measurement group_id="O3" value="1132" spread="38"/>
                    <measurement group_id="O4" value="1747" spread="178"/>
                    <measurement group_id="O5" value="3096" spread="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Multiple Dose Cmin for PF-06291874 - Part B</title>
        <description>Cmin was the lowest plasma concentration observed during the dosing interval. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
        <time_frame>Predose (0), 2, 4, 6, 8, 12, 19, 24 hours post dose on Day 14</time_frame>
        <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who have at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06291874 15 mg</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 30 mg</title>
            <description>Participants received PF-06291874 30 mg orally once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Dose Cmin for PF-06291874 - Part B</title>
          <description>Cmin was the lowest plasma concentration observed during the dosing interval. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
          <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who have at least 1 of the PK parameters of interest.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="339.5" spread="32"/>
                    <measurement group_id="O2" value="411.5" spread="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Multiple Dose Apparent Clearance (CL/F) for PF-06291874 - Part A</title>
        <description>CL/F was multiple dose apparent clearance. The 24-hour urine samples for PK analysis were collected on Day 14 over 2 collection periods (0-6 hours and 6-24 hours).</description>
        <time_frame>on Day 14 over 2 collection periods (0-6 hours and 6-24 hours).</time_frame>
        <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who have at least 1 of the PK parameters of interest. The number of participants analyzed was the number of participants contributing to the summary statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06291874 5 mg</title>
            <description>Participants received PF-06291874 5 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 15 mg</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PF-06291874 50 mg</title>
            <description>Participants received PF-06291874 50 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O4">
            <title>PF-06291874 100 mg</title>
            <description>Participants received PF-06291874 100 mg orally once daily for 28 days</description>
          </group>
          <group group_id="O5">
            <title>PF-06291874 150 mg</title>
            <description>Participants received PF-06291874 150 mg orally once daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Dose Apparent Clearance (CL/F) for PF-06291874 - Part A</title>
          <description>CL/F was multiple dose apparent clearance. The 24-hour urine samples for PK analysis were collected on Day 14 over 2 collection periods (0-6 hours and 6-24 hours).</description>
          <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who have at least 1 of the PK parameters of interest. The number of participants analyzed was the number of participants contributing to the summary statistics.</population>
          <units>L/hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.315" spread="42"/>
                    <measurement group_id="O2" value="1.275" spread="19"/>
                    <measurement group_id="O3" value="1.264" spread="30"/>
                    <measurement group_id="O4" value="1.258" spread="32"/>
                    <measurement group_id="O5" value="1.422" spread="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Multiple Dose CL/F for PF-06291874 - Part B</title>
        <description>CL/F was multiple dose apparent clearance. The 24-hour urine samples for PK analysis were collected on Day 14 over 2 collection periods (0-6 hours and 6-24 hours).</description>
        <time_frame>on Day 14 over 2 collection periods (0-6 hours and 6-24 hours).</time_frame>
        <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who have at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06291874 15 mg</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 30 mg</title>
            <description>Participants received PF-06291874 30 mg orally once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Dose CL/F for PF-06291874 - Part B</title>
          <description>CL/F was multiple dose apparent clearance. The 24-hour urine samples for PK analysis were collected on Day 14 over 2 collection periods (0-6 hours and 6-24 hours).</description>
          <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who have at least 1 of the PK parameters of interest.</population>
          <units>L/hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.300" spread="23"/>
                    <measurement group_id="O2" value="1.555" spread="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Multiple Dose Apparent Volume of Distribution (Vz/F) for PF-06291874- Part A and Part B</title>
        <description>Vz/F was apparent volume of distribution. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
        <time_frame>Predose (0), 2, 4, 6, 8, 12, 19, 24 hours post dose on Day 14</time_frame>
        <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who have at least 1 of the PK parameters of interest. This parameter was not calculated for treatment groups with only 24-hour sampling on Day 14(A: 100 mg and B: 30 mg), since the terminal phase was not well characterized.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06291874 5 mg</title>
            <description>Participants received PF-06291874 5 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 15 mg</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PF-06291874 50 mg</title>
            <description>Participants received PF-06291874 50 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O4">
            <title>PF-06291874 150 mg</title>
            <description>Participants received PF-06291874 150 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O5">
            <title>PF-06291874 15 mg - Part B</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Dose Apparent Volume of Distribution (Vz/F) for PF-06291874- Part A and Part B</title>
          <description>Vz/F was apparent volume of distribution. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
          <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who have at least 1 of the PK parameters of interest. This parameter was not calculated for treatment groups with only 24-hour sampling on Day 14(A: 100 mg and B: 30 mg), since the terminal phase was not well characterized.</population>
          <units>L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.37" spread="20"/>
                    <measurement group_id="O2" value="35.54" spread="21"/>
                    <measurement group_id="O3" value="40.47" spread="25"/>
                    <measurement group_id="O4" value="41.88" spread="29"/>
                    <measurement group_id="O5" value="42.20" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Multiple Dose Observed Accumulation Ratio (Rac) for PF-06291874 - Part A</title>
        <description>Rac was observed accumulation ratio. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
        <time_frame>Predose (0), 2, 4, 6, 8, 12, 19, 24 hours post dose on Day 14</time_frame>
        <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who have at least 1 of the PK parameters of interest. The number of participants analyzed was the number of participants contributing to the summary statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06291874 5 mg</title>
            <description>Participants received PF-06291874 5 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 15 mg</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PF-06291874 50 mg</title>
            <description>Participants received PF-06291874 50 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O4">
            <title>PF-06291874 100 mg</title>
            <description>Participants received PF-06291874 100 mg orally once daily for 28 days</description>
          </group>
          <group group_id="O5">
            <title>PF-06291874 150 mg</title>
            <description>Participants received PF-06291874 150 mg orally once daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Dose Observed Accumulation Ratio (Rac) for PF-06291874 - Part A</title>
          <description>Rac was observed accumulation ratio. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
          <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who have at least 1 of the PK parameters of interest. The number of participants analyzed was the number of participants contributing to the summary statistics.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.766" spread="38"/>
                    <measurement group_id="O2" value="1.724" spread="17"/>
                    <measurement group_id="O3" value="1.915" spread="17"/>
                    <measurement group_id="O4" value="1.847" spread="22"/>
                    <measurement group_id="O5" value="2.032" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Multiple Dose Rac for PF-06291874 - Part B</title>
        <description>Rac was observed accumulation ratio. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
        <time_frame>Predose (0), 2, 4, 6, 8, 12, 19, 24 hours post dose on Day 14</time_frame>
        <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who have at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06291874 15 mg</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 30 mg</title>
            <description>Participants received PF-06291874 30 mg orally once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Dose Rac for PF-06291874 - Part B</title>
          <description>Rac was observed accumulation ratio. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
          <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who have at least 1 of the PK parameters of interest.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.780" spread="17"/>
                    <measurement group_id="O2" value="1.709" spread="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Multiple Dose Rac for Cmax (Rac,Cmax) for PF-06291874 - Part A</title>
        <description>Rac,cmax was observed accumulation ratio for Cmax. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
        <time_frame>Predose (0), 2, 4, 6, 8, 12, 19, 24 hours post dose on Day 14</time_frame>
        <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who have at least 1 of the PK parameters of interest. The number of participants analyzed was the number of participants contributing to the summary statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06291874 5 mg</title>
            <description>Participants received PF-06291874 5 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 15 mg</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PF-06291874 50 mg</title>
            <description>Participants received PF-06291874 50 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O4">
            <title>PF-06291874 100 mg</title>
            <description>Participants received PF-06291874 100 mg orally once daily for 28 days</description>
          </group>
          <group group_id="O5">
            <title>PF-06291874 150 mg</title>
            <description>Participants received PF-06291874 150 mg orally once daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Dose Rac for Cmax (Rac,Cmax) for PF-06291874 - Part A</title>
          <description>Rac,cmax was observed accumulation ratio for Cmax. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
          <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who have at least 1 of the PK parameters of interest. The number of participants analyzed was the number of participants contributing to the summary statistics.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.575" spread="26"/>
                    <measurement group_id="O2" value="1.567" spread="23"/>
                    <measurement group_id="O3" value="1.698" spread="19"/>
                    <measurement group_id="O4" value="1.690" spread="25"/>
                    <measurement group_id="O5" value="1.812" spread="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Multiple Dose Rac,Cmax for PF-06291874 - Part B</title>
        <description>Rac,cmax was observed accumulation ratio for Cmax. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
        <time_frame>Predose (0), 2, 4, 6, 8, 12, 19, 24 hours post dose on Day 14</time_frame>
        <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who have at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06291874 15 mg</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 30 mg</title>
            <description>Participants received PF-06291874 30 mg orally once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Dose Rac,Cmax for PF-06291874 - Part B</title>
          <description>Rac,cmax was observed accumulation ratio for Cmax. Blood samples (3 mL) to provide a minimum of approximately 1.2 mL plasma for PK analysis were collected at 0, 2, 4, 6, 8, 12, 19, 24 hours post dose.</description>
          <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who have at least 1 of the PK parameters of interest.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.775" spread="22"/>
                    <measurement group_id="O2" value="1.610" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Multiple Dose Percent of Cumulative Amount of Drug Recovered Unchanged in Urine Over the Dosing Interval τ(Aetau%) for PF-06291874</title>
        <description>Aetau% was percent of cumulative amount of drug recovered unchanged in urine over the dosing interval τ. The 24-hour urine samples for PK analysis were collected on Day 14 over 2 collection periods (0-6 hours and 6-24 hours).</description>
        <time_frame>on Day 14 over 2 collection periods (0-6 hours and 6-24 hours).</time_frame>
        <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who have at least 1 of the PK parameters of interest. For treatment groups with dose&lt; 50 mg, all urine concentrations were below the lower limit of quantification (&lt;50.0 ng/mL) and hence no urine parameter was calculated including Aetau%.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06291874 50 mg</title>
            <description>Participants received PF-06291874 50 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 100 mg</title>
            <description>Participants received PF-06291874 100 mg orally once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>PF-06291874 150 mg</title>
            <description>Participants received PF-06291874 150 mg orally once daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Dose Percent of Cumulative Amount of Drug Recovered Unchanged in Urine Over the Dosing Interval τ(Aetau%) for PF-06291874</title>
          <description>Aetau% was percent of cumulative amount of drug recovered unchanged in urine over the dosing interval τ. The 24-hour urine samples for PK analysis were collected on Day 14 over 2 collection periods (0-6 hours and 6-24 hours).</description>
          <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who have at least 1 of the PK parameters of interest. For treatment groups with dose&lt; 50 mg, all urine concentrations were below the lower limit of quantification (&lt;50.0 ng/mL) and hence no urine parameter was calculated including Aetau%.</population>
          <units>percentage of dose</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0000" spread="19" lower_limit="0.000" upper_limit="0.0686"/>
                    <measurement group_id="O2" value="0.0000" spread="25" lower_limit="0.000" upper_limit="0.232"/>
                    <measurement group_id="O3" value="0.0000" spread="18" lower_limit="0.000" upper_limit="0.256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Multiple Dose Renal Clearance (CLr) for PF-06291874</title>
        <description>CLr was renal clearance. The 24 hour urine samples for PK analysis were collected on Day 14 over 2 collection periods (0-6 hours and 6-24 hours)</description>
        <time_frame>on Day 14 over 2 collection periods (0-6 hours and 6-24 hours).</time_frame>
        <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who have at least 1 of the PK parameters of interest. For treatment groups with dose&lt; 50 mg, all urine concentrations were below the lower limit of quantification (&lt;50.0 ng/mL) and hence no urine parameter was calculated including CLr.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06291874 50 mg</title>
            <description>Participants received PF-06291874 50 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 100 mg</title>
            <description>Participants received PF-06291874 100 mg orally once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>PF-06291874 150 mg</title>
            <description>Participants received PF-06291874 150 mg orally once daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Dose Renal Clearance (CLr) for PF-06291874</title>
          <description>CLr was renal clearance. The 24 hour urine samples for PK analysis were collected on Day 14 over 2 collection periods (0-6 hours and 6-24 hours)</description>
          <population>This PK Parameter Analysis Set was defined as all participants randomized and treated who have at least 1 of the PK parameters of interest. For treatment groups with dose&lt; 50 mg, all urine concentrations were below the lower limit of quantification (&lt;50.0 ng/mL) and hence no urine parameter was calculated including CLr.</population>
          <units>mL/hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0000" spread="19" lower_limit="0.000" upper_limit="0.441"/>
                    <measurement group_id="O2" value="0.0000" spread="25" lower_limit="0.000" upper_limit="2.25"/>
                    <measurement group_id="O3" value="0.0000" spread="18" lower_limit="0.000" upper_limit="2.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes From Baseline for Mean Daily Glucose (mg/dL) on Day 14 (AUC Approach) - Part A</title>
        <description>A MMTT was administered on Days -1 and 14 for all cohorts. Blood samples for analysis of glucose were collected at nominal time 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 10, 12, 15, 19 and 24 hours on Days -1 and 14 for all cohorts. MDG was computed by AUC24/24 hours of the glucose values measured.</description>
        <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 10, 12, 15, 19 and 24 hours on Days -1 and 14 for all cohorts, and on Day 28 for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B.</time_frame>
        <population>All subjects administered PF-06291874 or placebo were included in PD analysis. Placebo subjects within each cohort in Part A or B were pooled into a single placebo group for the inpatient portion of the study. Data collected from placebo subjects during the outpatient portion of study (Day 28) were also pooled separately for Parts A and B.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 14 or 28 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 5 mg</title>
            <description>Participants received PF-06291874 5 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PF-06291874 15 mg</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O4">
            <title>PF-06291874 50 mg</title>
            <description>Participants received PF-06291874 50 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O5">
            <title>PF-06291874 100 mg</title>
            <description>Participants received PF-06291874 100 mg orally once daily for 28 days</description>
          </group>
          <group group_id="O6">
            <title>PF-06291874 150 mg</title>
            <description>Participants received PF-06291874 150 mg orally once daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline for Mean Daily Glucose (mg/dL) on Day 14 (AUC Approach) - Part A</title>
          <description>A MMTT was administered on Days -1 and 14 for all cohorts. Blood samples for analysis of glucose were collected at nominal time 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 10, 12, 15, 19 and 24 hours on Days -1 and 14 for all cohorts. MDG was computed by AUC24/24 hours of the glucose values measured.</description>
          <population>All subjects administered PF-06291874 or placebo were included in PD analysis. Placebo subjects within each cohort in Part A or B were pooled into a single placebo group for the inpatient portion of the study. Data collected from placebo subjects during the outpatient portion of study (Day 28) were also pooled separately for Parts A and B.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.54" spread="58" lower_limit="-20.26" upper_limit="-2.81"/>
                    <measurement group_id="O2" value="-14.31" spread="28" lower_limit="-25.47" upper_limit="-3.16"/>
                    <measurement group_id="O3" value="-33.18" spread="38" lower_limit="-43.96" upper_limit="-22.40"/>
                    <measurement group_id="O4" value="-38.13" spread="178" lower_limit="-48.83" upper_limit="-27.43"/>
                    <measurement group_id="O5" value="-43.86" spread="47" lower_limit="-53.89" upper_limit="-33.84"/>
                    <measurement group_id="O6" value="-53.92" lower_limit="-64.72" upper_limit="-43.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Placebo was the Reference and each of the active doses was the Test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7457</p_value>
            <p_value_desc>Two-sided p-values are from analysis of Covariance (ANCOVA) model with treatment as a factor and baseline value as a covariate. P-values are not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least Square Mean Difference (Net)</param_type>
            <param_value>-2.77</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.532</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.93</ci_lower_limit>
            <ci_upper_limit>11.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Placebo was the Reference and each of the active doses was the Test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0108</p_value>
            <p_value_desc>Two-sided p-values are from analysis of Covariance (ANCOVA) model with treatment as a factor and baseline value as a covariate. P-values are not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least Square Mean Difference (Net)</param_type>
            <param_value>-21.64</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.334</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-35.47</ci_lower_limit>
            <ci_upper_limit>-7.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Placebo was the Reference and each of the active doses was the Test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0018</p_value>
            <p_value_desc>Two-sided p-values are from analysis of Covariance (ANCOVA) model with treatment as a factor and baseline value as a covariate. P-values are not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least Square Mean Difference (Net)</param_type>
            <param_value>-26.59</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.309</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-40.38</ci_lower_limit>
            <ci_upper_limit>-12.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Placebo was the Reference and each of the active doses was the Test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>Two-sided p-values are from analysis of Covariance (ANCOVA) model with treatment as a factor and baseline value as a covariate. P-values are not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least Square Mean Difference (Net)</param_type>
            <param_value>-32.33</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.038</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-45.66</ci_lower_limit>
            <ci_upper_limit>-18.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Placebo was the Reference and each of the active doses was the Test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Two-sided p-values are from analysis of Covariance (ANCOVA) model with treatment as a factor and baseline value as a covariate. P-values are not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least Square Mean Difference (Net)</param_type>
            <param_value>-42.39</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.340</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-56.23</ci_lower_limit>
            <ci_upper_limit>-28.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes From Baseline for Mean Daily Glucose (mg/dL) on Day 14 (AUC Approach) - Part B</title>
        <description>A MMTT was administered on Days -1 and 14 for all cohorts. Blood samples for analysis of glucose were collected at nominal time 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 10, 12, 15, 19 and 24 hours on Days -1 and 14 for all cohorts. MDG was computed by AUC24/24 hours of the glucose values measured.</description>
        <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 10, 12, 15, 19 and 24 hours on Days -1 and 14 for all cohorts, and on Day 28 for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B.</time_frame>
        <population>All subjects administered PF-06291874 or placebo were included in PD analysis. Placebo subjects within each cohort in Part A or B were pooled into a single placebo group for the inpatient portion of the study. Data collected from placebo subjects during the outpatient portion of study (Day 28) were also pooled separately for Parts A and B.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06291874 15 mg</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 30 mg</title>
            <description>Participants received PF-06291874 30 mg orally once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 14 or 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline for Mean Daily Glucose (mg/dL) on Day 14 (AUC Approach) - Part B</title>
          <description>A MMTT was administered on Days -1 and 14 for all cohorts. Blood samples for analysis of glucose were collected at nominal time 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 10, 12, 15, 19 and 24 hours on Days -1 and 14 for all cohorts. MDG was computed by AUC24/24 hours of the glucose values measured.</description>
          <population>All subjects administered PF-06291874 or placebo were included in PD analysis. Placebo subjects within each cohort in Part A or B were pooled into a single placebo group for the inpatient portion of the study. Data collected from placebo subjects during the outpatient portion of study (Day 28) were also pooled separately for Parts A and B.</population>
          <units>ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.85" spread="32" lower_limit="-32.56" upper_limit="-9.15"/>
                    <measurement group_id="O2" value="-50.65" spread="217" lower_limit="-60.58" upper_limit="-40.71"/>
                    <measurement group_id="O3" value="-31.32" lower_limit="-42.12" upper_limit="-20.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Placebo was the Reference and each of the active doses was the Test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2790</p_value>
            <p_value_desc>Two-sided p-values are from ANCOVA model with treatment as a factor and baseline value as a covariate. P-values are not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least Square Mean Difference (Net)</param_type>
            <param_value>10.47</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.621</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.50</ci_lower_limit>
            <ci_upper_limit>26.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Placebo was the Reference and each of the active doses was the Test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0299</p_value>
            <p_value_desc>Two-sided p-values are from ANCOVA model with treatment as a factor and baseline value as a covariate. P-values are not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least Square Mean Difference (Net)</param_type>
            <param_value>-19.33</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.777</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>-33.89</ci_lower_limit>
            <ci_upper_limit>-4.76</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes From Baseline for Mean Daily Glucose (mg/dL) on Day 28 (AUC Approach)</title>
        <description>A MMTT was administered on Days -1 for all cohorts, and on Day 28 for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B. Blood samples for analysis of glucose were collected at nominal time 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 10, 12, 15, 19 and 24 hours on Days -1 and 14 for all cohorts, and on Day 28 for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B. MDG was computed by AUC24/24 hours of the glucose values measured.</description>
        <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 10, 12, 15, 19 and 24 hours on Days -1 and 14 for all cohorts, and on Day 28 for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B.</time_frame>
        <population>All subjects administered PF-06291874 or placebo were included in PD analysis. Placebo subjects within each cohort in Part A or B were pooled into a single placebo group for the inpatient portion of the study. Data collected from placebo subjects during the outpatient portion of study (Day 28) were also pooled separately for Parts A and B.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 14 or 28 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 100 mg</title>
            <description>Participants received PF-06291874 100 mg orally once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Placebo - Part B</title>
            <description>Participants received placebo orally once daily for 14 or 28 days</description>
          </group>
          <group group_id="O4">
            <title>PF-06291874 30 mg - Part B</title>
            <description>Participants received PF-06291874 30 mg orally once daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline for Mean Daily Glucose (mg/dL) on Day 28 (AUC Approach)</title>
          <description>A MMTT was administered on Days -1 for all cohorts, and on Day 28 for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B. Blood samples for analysis of glucose were collected at nominal time 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 10, 12, 15, 19 and 24 hours on Days -1 and 14 for all cohorts, and on Day 28 for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B. MDG was computed by AUC24/24 hours of the glucose values measured.</description>
          <population>All subjects administered PF-06291874 or placebo were included in PD analysis. Placebo subjects within each cohort in Part A or B were pooled into a single placebo group for the inpatient portion of the study. Data collected from placebo subjects during the outpatient portion of study (Day 28) were also pooled separately for Parts A and B.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.99" spread="58" lower_limit="-17.73" upper_limit="3.75"/>
                    <measurement group_id="O2" value="-36.42" spread="28" lower_limit="-43.44" upper_limit="-29.39"/>
                    <measurement group_id="O3" value="-30.10" spread="38" lower_limit="-40.05" upper_limit="-20.16"/>
                    <measurement group_id="O4" value="-42.00" spread="178" lower_limit="-49.29" upper_limit="-34.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Placebo was the Reference and each of the active doses was the Test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <p_value_desc>Two-sided p-values are from analysis of Covariance (ANCOVA) model with treatment as a factor and baseline value as a covariate. P-values are not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least Square Mean Difference (Net)</param_type>
            <param_value>-29.43</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.609</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-42.28</ci_lower_limit>
            <ci_upper_limit>-16.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Placebo was the Reference and each of the active doses was the Test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1133</p_value>
            <p_value_desc>Two-sided p-values are from analysis of Covariance (ANCOVA) model with treatment as a factor and baseline value as a covariate. P-values are not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least Square Mean Difference (Net)</param_type>
            <param_value>-11.89</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.321</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.26</ci_lower_limit>
            <ci_upper_limit>0.48</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes Relative to Baseline (Ratio) of AUC0-4 for Glucose Following MMTT on Day 14 - Part A</title>
        <description>Blood samples for analysis of glucose were collected at nominal time 0, 0.25, 0.5, 1, 1.5, 2, 3, and 4 hours on Days -1 and 14 for all cohorts, and on Day 28 for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B. AUC0-4 and natural log transformed AUC0-4 were calculated for each day.</description>
        <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 10, 12, 15, and 19 hours on Days -1 and 14 for all cohorts, and on Day 28 for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B.</time_frame>
        <population>All subjects administered PF-06291874 or placebo were included in PD analysis. Placebo subjects within each cohort in Part A or B were pooled into a single placebo group for the inpatient portion of the study. Data collected from placebo subjects during the outpatient portion of study (Day 28) were also pooled separately for Parts A and B.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 14 or 28 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 5 mg</title>
            <description>Participants received PF-06291874 5 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PF-06291874 15 mg</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O4">
            <title>PF-06291874 50 mg</title>
            <description>Participants received PF-06291874 50 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O5">
            <title>PF-06291874 100 mg</title>
            <description>Participants received PF-06291874 100 mg orally once daily for 28 days</description>
          </group>
          <group group_id="O6">
            <title>PF-06291874 150 mg</title>
            <description>Participants received PF-06291874 150 mg orally once daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Changes Relative to Baseline (Ratio) of AUC0-4 for Glucose Following MMTT on Day 14 - Part A</title>
          <description>Blood samples for analysis of glucose were collected at nominal time 0, 0.25, 0.5, 1, 1.5, 2, 3, and 4 hours on Days -1 and 14 for all cohorts, and on Day 28 for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B. AUC0-4 and natural log transformed AUC0-4 were calculated for each day.</description>
          <population>All subjects administered PF-06291874 or placebo were included in PD analysis. Placebo subjects within each cohort in Part A or B were pooled into a single placebo group for the inpatient portion of the study. Data collected from placebo subjects during the outpatient portion of study (Day 28) were also pooled separately for Parts A and B.</population>
          <units>ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" lower_limit="0.82" upper_limit="0.94"/>
                    <measurement group_id="O2" value="0.87" lower_limit="0.80" upper_limit="0.94"/>
                    <measurement group_id="O3" value="0.75" lower_limit="0.69" upper_limit="0.82"/>
                    <measurement group_id="O4" value="0.74" lower_limit="0.69" upper_limit="0.81"/>
                    <measurement group_id="O5" value="0.72" lower_limit="0.67" upper_limit="0.77"/>
                    <measurement group_id="O6" value="0.67" lower_limit="0.62" upper_limit="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Placebo was the Reference and each of the active doses was the Test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8530</p_value>
            <p_value_desc>Two-sided p-values are from analysis of Covariance (ANCOVA) model with treatment as a factor and baseline value as a covariate using the natural log-transformed AUC0-4. P-values are not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Ratio</param_type>
            <param_value>0.99</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.066</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Placebo was the Reference and each of the active doses was the Test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0172</p_value>
            <p_value_desc>Two-sided p-values are from analysis of Covariance (ANCOVA) model with treatment as a factor and baseline value as a covariate using the natural log-transformed AUC0-4. P-values are not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Ratio</param_type>
            <param_value>0.86</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.065</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Placebo was the Reference and each of the active doses was the Test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0106</p_value>
            <p_value_desc>Two-sided p-values are from analysis of Covariance (ANCOVA) model with treatment as a factor and baseline value as a covariate using the natural log-transformed AUC0-4. P-values are not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Ratio</param_type>
            <param_value>0.85</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.064</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Placebo was the Reference and each of the active doses was the Test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0012</p_value>
            <p_value_desc>Two-sided p-values are from analysis of Covariance (ANCOVA) model with treatment as a factor and baseline value as a covariate using the natural log-transformed AUC0-4. P-values are not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Ratio</param_type>
            <param_value>0.82</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.062</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>0.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Placebo was the Reference and each of the active doses was the Test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Two-sided p-values are from analysis of Covariance (ANCOVA) model with treatment as a factor and baseline value as a covariate using the natural log-transformed AUC0-4. P-values are not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Ratio</param_type>
            <param_value>0.77</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.065</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes Relative to Baseline (Ratio) of AUC0-4 for Glucose Following MMTT on Day 14 - Part B</title>
        <description>Blood samples for analysis of glucose were collected at nominal time 0, 0.25, 0.5, 1, 1.5, 2, 3, and 4 hours on Days -1 and 14 for all cohorts, and on Day 28 for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B. AUC0-4 and natural log transformed AUC0-4 were calculated for each day.</description>
        <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 10, 12, 15, and 19 hours on Days -1 and 14 for all cohorts, and on Day 28 for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B.</time_frame>
        <population>All subjects administered PF-06291874 or placebo were included in PD analysis. Placebo subjects within each cohort in Part A or B were pooled into a single placebo group for the inpatient portion of the study. Data collected from placebo subjects during the outpatient portion of study (Day 28) were also pooled separately for Parts A and B.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06291874 15 mg</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 30 mg</title>
            <description>Participants received PF-06291874 30 mg orally once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 14 or 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Changes Relative to Baseline (Ratio) of AUC0-4 for Glucose Following MMTT on Day 14 - Part B</title>
          <description>Blood samples for analysis of glucose were collected at nominal time 0, 0.25, 0.5, 1, 1.5, 2, 3, and 4 hours on Days -1 and 14 for all cohorts, and on Day 28 for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B. AUC0-4 and natural log transformed AUC0-4 were calculated for each day.</description>
          <population>All subjects administered PF-06291874 or placebo were included in PD analysis. Placebo subjects within each cohort in Part A or B were pooled into a single placebo group for the inpatient portion of the study. Data collected from placebo subjects during the outpatient portion of study (Day 28) were also pooled separately for Parts A and B.</population>
          <units>ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" spread="32" lower_limit="0.74" upper_limit="0.89"/>
                    <measurement group_id="O2" value="0.74" spread="217" lower_limit="0.69" upper_limit="0.80"/>
                    <measurement group_id="O3" value="0.83" lower_limit="0.76" upper_limit="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Placebo was the Reference and each of the active doses was the Test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7804</p_value>
            <p_value_desc>Two-sided p-values are from analysis of ANCOVA model with treatment as a factor and baseline value as a covariate using the natural log-transformed AUC0-4. P-values are not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Ratio</param_type>
            <param_value>0.98</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.075</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Placebo was the Reference and each of the active doses was the Test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0908</p_value>
            <p_value_desc>Two-sided p-values are from ANCOVA model with treatment as a factor and baseline value as a covariate using the natural log-transformed AUC0-4. P-values are not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Ratio</param_type>
            <param_value>0.88</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.068</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes Relative to Baseline (Ratio) of AUC0-4 for Glucose Following MMTT on Day 28</title>
        <description>Blood samples for analysis of glucose were collected at nominal time 0, 0.25, 0.5, 1, 1.5, 2, 3, and 4 hours on Days -1 and 14 for all cohorts, and on Day 28 for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B. AUC0-4 and natural log transformed AUC0-4 were calculated for each day.</description>
        <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 10, 12, 15, and 19 hours on Days -1 and 14 for all cohorts, and on Day 28 for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B.</time_frame>
        <population>All subjects administered PF-06291874 or placebo were included in PD analysis. Placebo subjects within each cohort in Part A or B were pooled into a single placebo group for the inpatient portion of the study. Data collected from placebo subjects during the outpatient portion of study (Day 28) were also pooled separately for Parts A and B.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 14 or 28 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 100 mg</title>
            <description>Participants received PF-06291874 100 mg orally once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Placebo - Part B</title>
            <description>Participants received placebo orally once daily for 14 or 28 days</description>
          </group>
          <group group_id="O4">
            <title>PF-06291874 30 mg - Part B</title>
            <description>Participants received PF-06291874 30 mg orally once daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Changes Relative to Baseline (Ratio) of AUC0-4 for Glucose Following MMTT on Day 28</title>
          <description>Blood samples for analysis of glucose were collected at nominal time 0, 0.25, 0.5, 1, 1.5, 2, 3, and 4 hours on Days -1 and 14 for all cohorts, and on Day 28 for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B. AUC0-4 and natural log transformed AUC0-4 were calculated for each day.</description>
          <population>All subjects administered PF-06291874 or placebo were included in PD analysis. Placebo subjects within each cohort in Part A or B were pooled into a single placebo group for the inpatient portion of the study. Data collected from placebo subjects during the outpatient portion of study (Day 28) were also pooled separately for Parts A and B.</population>
          <units>ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" spread="58" lower_limit="0.91" upper_limit="1.14"/>
                    <measurement group_id="O2" value="0.79" spread="28" lower_limit="0.73" upper_limit="0.85"/>
                    <measurement group_id="O3" value="0.89" spread="38" lower_limit="0.80" upper_limit="0.99"/>
                    <measurement group_id="O4" value="0.78" spread="178" lower_limit="0.73" upper_limit="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Placebo was the Reference and each of the active doses was the Test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0027</p_value>
            <p_value_desc>Two-sided p-values are from ANCOVA model with treatment as a factor and baseline value as a covariate using the natural log-transformed AUC0-4. P-values are not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Ratio</param_type>
            <param_value>0.77</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.083</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>0.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Placebo was the Reference and each of the active doses was the Test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0908</p_value>
            <p_value_desc>Two-sided p-values are from ANCOVA model with treatment as a factor and baseline value as a covariate using the natural log-transformed AUC0-4. P-values are not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Ratio</param_type>
            <param_value>0.88</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.079</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Changes From Baseline of AUC0-4 for Glucagon Following MMTT on Day 14 - Part A</title>
        <description>Blood samples for analysis of insulin, C-peptide, glucagon and glucagon-like peptide 1 (GLP-1) were collected at nominal time 0, 0.25, 0.5, 1, 1.5, 2, 3, 4 hours on Days -1 and 14 for all cohorts, and on Day 28 and follow-up visit for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B. AUC0-4 and natural log transformed AUC0-4 were calculated for each day.</description>
        <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 3, 4 hours on Days -1 and 14 for all cohorts, and on Day 28 and follow-up visit for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B.</time_frame>
        <population>All subjects administered PF-06291874 or placebo were included in PD analysis. Placebo subjects within each cohort in Part A or B were pooled into a single placebo group for the inpatient portion of the study. Data collected from placebo subjects during the outpatient portion of study (Day 28) were also pooled separately for Parts A and B.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 14 or 28 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 5 mg</title>
            <description>Participants received PF-06291874 5 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PF-06291874 15 mg</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O4">
            <title>PF-06291874 50 mg</title>
            <description>Participants received PF-06291874 50 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O5">
            <title>PF-06291874 100 mg</title>
            <description>Participants received PF-06291874 100 mg orally once daily for 28 days</description>
          </group>
          <group group_id="O6">
            <title>PF-06291874 150 mg</title>
            <description>Participants received PF-06291874 150 mg orally once daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Changes From Baseline of AUC0-4 for Glucagon Following MMTT on Day 14 - Part A</title>
          <description>Blood samples for analysis of insulin, C-peptide, glucagon and glucagon-like peptide 1 (GLP-1) were collected at nominal time 0, 0.25, 0.5, 1, 1.5, 2, 3, 4 hours on Days -1 and 14 for all cohorts, and on Day 28 and follow-up visit for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B. AUC0-4 and natural log transformed AUC0-4 were calculated for each day.</description>
          <population>All subjects administered PF-06291874 or placebo were included in PD analysis. Placebo subjects within each cohort in Part A or B were pooled into a single placebo group for the inpatient portion of the study. Data collected from placebo subjects during the outpatient portion of study (Day 28) were also pooled separately for Parts A and B.</population>
          <units>Percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.38" spread="20.396" lower_limit="0.82" upper_limit="0.94"/>
                    <measurement group_id="O2" value="12.17" spread="11.910" lower_limit="0.80" upper_limit="0.94"/>
                    <measurement group_id="O3" value="50.45" spread="37.048" lower_limit="0.69" upper_limit="0.82"/>
                    <measurement group_id="O4" value="46.90" spread="30.179" lower_limit="0.69" upper_limit="0.81"/>
                    <measurement group_id="O5" value="142.62" spread="113.394" lower_limit="0.67" upper_limit="0.77"/>
                    <measurement group_id="O6" value="214.32" spread="118.612" lower_limit="0.62" upper_limit="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Changes From Baseline of AUC0-4 for Glucagon Following MMTT on Day 14 - Part B</title>
        <description>Blood samples for analysis of insulin, C-peptide, glucagon and glucagon-like peptide 1 (GLP-1) were collected at nominal time 0, 0.25, 0.5, 1, 1.5, 2, 3, 4 hours on Days -1 and 14 for all cohorts, and on Day 28 and follow-up visit for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B. AUC0-4 and natural log transformed AUC0-4 were calculated for each day.</description>
        <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 3, 4 hours on Days -1 and 14 for all cohorts, and on Day 28 and follow-up visit for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B.</time_frame>
        <population>All subjects administered PF-06291874 or placebo were included in PD analysis. Placebo subjects within each cohort in Part A or B were pooled into a single placebo group for the inpatient portion of the study. Data collected from placebo subjects during the outpatient portion of study (Day 28) were also pooled separately for Parts A and B.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06291874 15 mg</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 30 mg</title>
            <description>Participants received PF-06291874 30 mg orally once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 14 or 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Changes From Baseline of AUC0-4 for Glucagon Following MMTT on Day 14 - Part B</title>
          <description>Blood samples for analysis of insulin, C-peptide, glucagon and glucagon-like peptide 1 (GLP-1) were collected at nominal time 0, 0.25, 0.5, 1, 1.5, 2, 3, 4 hours on Days -1 and 14 for all cohorts, and on Day 28 and follow-up visit for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B. AUC0-4 and natural log transformed AUC0-4 were calculated for each day.</description>
          <population>All subjects administered PF-06291874 or placebo were included in PD analysis. Placebo subjects within each cohort in Part A or B were pooled into a single placebo group for the inpatient portion of the study. Data collected from placebo subjects during the outpatient portion of study (Day 28) were also pooled separately for Parts A and B.</population>
          <units>Percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.19" spread="23.47" lower_limit="0.74" upper_limit="0.89"/>
                    <measurement group_id="O2" value="50.35" spread="24.33" lower_limit="0.69" upper_limit="0.80"/>
                    <measurement group_id="O3" value="7.23" spread="22.59" lower_limit="0.76" upper_limit="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Changes From Baseline of AUC0-4 for Glucagon Following MMTT on Day 28</title>
        <description>Blood samples for analysis of insulin, C-peptide, glucagon and GLP-1 were collected at nominal time 0, 0.25, 0.5, 1, 1.5, 2, 3, 4 hours on Days -1 and 14 for all cohorts, and on Day 28 and follow-up visit for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B. AUC0-4 and natural log transformed AUC0-4 were calculated for each day.</description>
        <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 3, 4 hours on Days -1 and 14 for all cohorts, and on Day 28 and follow-up visit for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B.</time_frame>
        <population>All subjects administered PF-06291874 or placebo were included in PD analysis. Placebo subjects within each cohort in Part A or B were pooled into a single placebo group for the inpatient portion of the study. Data collected from placebo subjects during the outpatient portion of study (Day 28) were also pooled separately for Parts A and B.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 14 or 28 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 100 mg</title>
            <description>Participants received PF-06291874 100 mg orally once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Placebo - Part B</title>
            <description>Participants received placebo orally once daily for 14 or 28 days</description>
          </group>
          <group group_id="O4">
            <title>PF-06291874 30 mg</title>
            <description>Participants received PF-06291874 30 mg orally once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Changes From Baseline of AUC0-4 for Glucagon Following MMTT on Day 28</title>
          <description>Blood samples for analysis of insulin, C-peptide, glucagon and GLP-1 were collected at nominal time 0, 0.25, 0.5, 1, 1.5, 2, 3, 4 hours on Days -1 and 14 for all cohorts, and on Day 28 and follow-up visit for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B. AUC0-4 and natural log transformed AUC0-4 were calculated for each day.</description>
          <population>All subjects administered PF-06291874 or placebo were included in PD analysis. Placebo subjects within each cohort in Part A or B were pooled into a single placebo group for the inpatient portion of the study. Data collected from placebo subjects during the outpatient portion of study (Day 28) were also pooled separately for Parts A and B.</population>
          <units>Percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.04" spread="52.52" lower_limit="0.91" upper_limit="1.14"/>
                    <measurement group_id="O2" value="125.15" spread="120.82" lower_limit="0.73" upper_limit="0.85"/>
                    <measurement group_id="O3" value="-1.19" spread="29.18" lower_limit="0.80" upper_limit="0.99"/>
                    <measurement group_id="O4" value="36.49" spread="45.17" lower_limit="0.73" upper_limit="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes Relative to Baseline (Ratio) of AUC0-4 for Insulin Following MMTT on Day 14 - Part A</title>
        <description>Blood samples for analysis of insulin, C-peptide, glucagon and GLP-1 were collected at nominal time 0, 0.25, 0.5, 1, 1.5, 2, 3, 4 hours on Days -1 and 14 for all cohorts, and on Day 28 and follow-up visit for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B. AUC0-4 and natural log transformed AUC0-4 were calculated for each day.</description>
        <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 3, 4 hours on Days -1 and 14 for all cohorts, and on Day 28 and follow-up visit for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B.</time_frame>
        <population>All subjects administered PF-06291874 or placebo were included in PD analysis. Placebo subjects within each cohort in Part A or B were pooled into a single placebo group for the inpatient portion of the study. The number of participants analyzed was the number of participants contributing to the summary statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 14 or 28 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 5 mg</title>
            <description>Participants received PF-06291874 5 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PF-06291874 15 mg</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O4">
            <title>PF-06291874 50 mg</title>
            <description>Participants received PF-06291874 50 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O5">
            <title>PF-06291874 100 mg</title>
            <description>Participants received PF-06291874 100 mg orally once daily for 28 days</description>
          </group>
          <group group_id="O6">
            <title>PF-06291874 150 mg</title>
            <description>Participants received PF-06291874 150 mg orally once daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Changes Relative to Baseline (Ratio) of AUC0-4 for Insulin Following MMTT on Day 14 - Part A</title>
          <description>Blood samples for analysis of insulin, C-peptide, glucagon and GLP-1 were collected at nominal time 0, 0.25, 0.5, 1, 1.5, 2, 3, 4 hours on Days -1 and 14 for all cohorts, and on Day 28 and follow-up visit for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B. AUC0-4 and natural log transformed AUC0-4 were calculated for each day.</description>
          <population>All subjects administered PF-06291874 or placebo were included in PD analysis. Placebo subjects within each cohort in Part A or B were pooled into a single placebo group for the inpatient portion of the study. The number of participants analyzed was the number of participants contributing to the summary statistics.</population>
          <units>ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" lower_limit="0.91" upper_limit="1.15"/>
                    <measurement group_id="O2" value="1.01" lower_limit="0.86" upper_limit="1.17"/>
                    <measurement group_id="O3" value="0.95" lower_limit="0.82" upper_limit="1.11"/>
                    <measurement group_id="O4" value="0.85" lower_limit="0.73" upper_limit="1.00"/>
                    <measurement group_id="O5" value="0.91" lower_limit="0.80" upper_limit="1.04"/>
                    <measurement group_id="O6" value="1.00" lower_limit="0.87" upper_limit="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Placebo was the Reference and each of the active doses was the Test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8723</p_value>
            <p_value_desc>Two-sided p-values are from ANCOVA model with treatment as a factor and baseline value as a covariate using the natural log-transformed AUC0-4. P-values are not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Ratio</param_type>
            <param_value>0.98</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.123</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Placebo was the Reference and each of the active doses was the Test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5158</p_value>
            <p_value_desc>Two-sided p-values are from ANCOVA model with treatment as a factor and baseline value as a covariate using the natural log-transformed AUC0-4. P-values are not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Ratio</param_type>
            <param_value>0.93</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.124</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Placebo was the Reference and each of the active doses was the Test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1258</p_value>
            <p_value_desc>Two-sided p-values are from ANCOVA model with treatment as a factor and baseline value as a covariate using the natural log-transformed AUC0-4. P-values are not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Ratio</param_type>
            <param_value>0.83</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.126</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Placebo was the Reference and each of the active doses was the Test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2883</p_value>
            <p_value_desc>Two-sided p-values are from ANCOVA model with treatment as a factor and baseline value as a covariate using the natural log-transformed AUC0-4. P-values are not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Ratio</param_type>
            <param_value>0.89</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.115</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Placebo was the Reference and each of the active doses was the Test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8437</p_value>
            <p_value_desc>Two-sided p-values are from ANCOVA model with treatment as a factor and baseline value as a covariate using the natural log-transformed AUC0-4. P-values are not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Ratio</param_type>
            <param_value>0.98</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.120</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes Relative to Baseline (Ratio) of AUC0-4 for Insulin Following MMTT on Day 14 - Part B</title>
        <description>Blood samples for analysis of insulin, C-peptide, glucagon and GLP-1 were collected at nominal time 0, 0.25, 0.5, 1, 1.5, 2, 3, 4 hours on Days -1 and 14 for all cohorts, and on Day 28 and follow-up visit for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B. AUC0-4 and natural log transformed AUC0-4 were calculated for each day.</description>
        <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 3, 4 hours on Days -1 and 14 for all cohorts, and on Day 28 and follow-up visit for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B.</time_frame>
        <population>All subjects administered PF-06291874 or placebo were included in PD analysis. Placebo subjects within each cohort in Part A or B were pooled into a single placebo group for the inpatient portion of the study. Data collected from placebo subjects during the outpatient portion of study (Day 28) were also pooled separately for Parts A and B.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06291874 15 mg</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 30 mg</title>
            <description>Participants received PF-06291874 30 mg orally once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 14 or 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Changes Relative to Baseline (Ratio) of AUC0-4 for Insulin Following MMTT on Day 14 - Part B</title>
          <description>Blood samples for analysis of insulin, C-peptide, glucagon and GLP-1 were collected at nominal time 0, 0.25, 0.5, 1, 1.5, 2, 3, 4 hours on Days -1 and 14 for all cohorts, and on Day 28 and follow-up visit for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B. AUC0-4 and natural log transformed AUC0-4 were calculated for each day.</description>
          <population>All subjects administered PF-06291874 or placebo were included in PD analysis. Placebo subjects within each cohort in Part A or B were pooled into a single placebo group for the inpatient portion of the study. Data collected from placebo subjects during the outpatient portion of study (Day 28) were also pooled separately for Parts A and B.</population>
          <units>Ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" spread="32" lower_limit="0.95" upper_limit="1.33"/>
                    <measurement group_id="O2" value="1.10" spread="217" lower_limit="0.95" upper_limit="1.28"/>
                    <measurement group_id="O3" value="1.01" lower_limit="0.85" upper_limit="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Placebo was the Reference and each of the active doses was the Test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4405</p_value>
            <p_value_desc>Two-sided p-values are from ANCOVA model with treatment as a factor and baseline value as a covariate using the natural log-transformed AUC0-4. P-values are not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Ratio</param_type>
            <param_value>1.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.154</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Placebo was the Reference and each of the active doses was the Test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5178</p_value>
            <p_value_desc>Two-sided p-values are from ANCOVA model with treatment as a factor and baseline value as a covariate using the natural log-transformed AUC0-4. P-values are not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Ratio</param_type>
            <param_value>1.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.146</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.37</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes Relative to Baseline (Ratio) of AUC0-4 for Insulin Following MMTT on Day 28</title>
        <description>Blood samples for analysis of insulin, C-peptide, glucagon and GLP-1 were collected at nominal time 0, 0.25, 0.5, 1, 1.5, 2, 3, 4 hours on Days -1 and 14 for all cohorts, and on Day 28 and follow-up visit for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B. AUC0-4 and natural log transformed AUC0-4 were calculated for each day.</description>
        <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 3, 4 hours on Days -1 and 14 for all cohorts, and on Day 28 and follow-up visit for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B.</time_frame>
        <population>All subjects administered PF-06291874 or placebo were included in PD analysis. Placebo subjects within each cohort in Part A or B were pooled into a single placebo group for the inpatient portion of the study. Data collected from placebo subjects during the outpatient portion of study (Day 28) were also pooled separately for Parts A and B.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 14 or 28 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 100 mg</title>
            <description>Participants received PF-06291874 100 mg orally once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Placebo - Part B</title>
            <description>Participants received placebo orally once daily for 14 or 28 days</description>
          </group>
          <group group_id="O4">
            <title>PF-06291874 30 mg</title>
            <description>Participants received PF-06291874 30 mg orally once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Changes Relative to Baseline (Ratio) of AUC0-4 for Insulin Following MMTT on Day 28</title>
          <description>Blood samples for analysis of insulin, C-peptide, glucagon and GLP-1 were collected at nominal time 0, 0.25, 0.5, 1, 1.5, 2, 3, 4 hours on Days -1 and 14 for all cohorts, and on Day 28 and follow-up visit for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B. AUC0-4 and natural log transformed AUC0-4 were calculated for each day.</description>
          <population>All subjects administered PF-06291874 or placebo were included in PD analysis. Placebo subjects within each cohort in Part A or B were pooled into a single placebo group for the inpatient portion of the study. Data collected from placebo subjects during the outpatient portion of study (Day 28) were also pooled separately for Parts A and B.</population>
          <units>Ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.22" spread="58" lower_limit="0.97" upper_limit="1.54"/>
                    <measurement group_id="O2" value="0.85" spread="28" lower_limit="0.73" upper_limit="0.99"/>
                    <measurement group_id="O3" value="0.77" spread="38" lower_limit="0.62" upper_limit="0.96"/>
                    <measurement group_id="O4" value="0.93" spread="178" lower_limit="0.79" upper_limit="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Placebo was the Reference and each of the active doses was the Test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0340</p_value>
            <p_value_desc>Two-sided p-values are from ANCOVA model with treatment as a factor and baseline value as a covariate using the natural log-transformed AUC0-4. P-values are not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Ratio</param_type>
            <param_value>0.69</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.181</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>0.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Placebo was the Reference and each of the active doses was the Test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2519</p_value>
            <p_value_desc>Two-sided p-values are from ANCOVA model with treatment as a factor and baseline value as a covariate using the natural log-transformed AUC0-4. P-values are not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Ratio</param_type>
            <param_value>1.20</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.173</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>1.58</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes Relative to Baseline (Ratio) of AUC0-4 for C-Peptide Following MMTT on Day 14 - Part A</title>
        <description>Blood samples for analysis of insulin, C-peptide, glucagon and GLP-1 were collected at nominal time 0, 0.25, 0.5, 1, 1.5, 2, 3, 4 hours on Days -1 and 14 for all cohorts, and on Day 28 and follow-up visit for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B. AUC0-4 and natural log transformed AUC0-4 were calculated for each day.</description>
        <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 3, 4 hours on Days -1 and 14 for all cohorts, and on Day 28 and follow-up visit for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B.</time_frame>
        <population>All subjects administered PF-06291874 or placebo were included in PD analysis. Placebo subjects within each cohort in Part A or B were pooled into a single placebo group for the inpatient portion of the study. Data collected from placebo subjects during the outpatient portion of study (Day 28) were also pooled separately for Parts A and B.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 14 or 28 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 5 mg</title>
            <description>Participants received PF-06291874 5 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PF-06291874 15 mg</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O4">
            <title>PF-06291874 50 mg</title>
            <description>Participants received PF-06291874 50 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O5">
            <title>PF-06291874 100 mg</title>
            <description>Participants received PF-06291874 100 mg orally once daily for 28 days</description>
          </group>
          <group group_id="O6">
            <title>PF-06291874 150 mg</title>
            <description>Participants received PF-06291874 150 mg orally once daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Changes Relative to Baseline (Ratio) of AUC0-4 for C-Peptide Following MMTT on Day 14 - Part A</title>
          <description>Blood samples for analysis of insulin, C-peptide, glucagon and GLP-1 were collected at nominal time 0, 0.25, 0.5, 1, 1.5, 2, 3, 4 hours on Days -1 and 14 for all cohorts, and on Day 28 and follow-up visit for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B. AUC0-4 and natural log transformed AUC0-4 were calculated for each day.</description>
          <population>All subjects administered PF-06291874 or placebo were included in PD analysis. Placebo subjects within each cohort in Part A or B were pooled into a single placebo group for the inpatient portion of the study. Data collected from placebo subjects during the outpatient portion of study (Day 28) were also pooled separately for Parts A and B.</population>
          <units>ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96" lower_limit="0.88" upper_limit="1.04"/>
                    <measurement group_id="O2" value="1.01" lower_limit="0.92" upper_limit="1.12"/>
                    <measurement group_id="O3" value="0.94" lower_limit="0.85" upper_limit="1.04"/>
                    <measurement group_id="O4" value="0.89" lower_limit="0.80" upper_limit="0.99"/>
                    <measurement group_id="O5" value="0.95" lower_limit="0.87" upper_limit="1.05"/>
                    <measurement group_id="O6" value="1.03" lower_limit="0.94" upper_limit="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Placebo was the Reference and each of the active doses was the Test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4579</p_value>
            <p_value_desc>Two-sided p-values are from ANCOVA model with treatment as a factor and baseline value as a covariate using the natural log-transformed AUC0-4. P-values are not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Ratio</param_type>
            <param_value>1.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.079</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Placebo was the Reference and each of the active doses was the Test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8144</p_value>
            <p_value_desc>Two-sided p-values are from ANCOVA model with treatment as a factor and baseline value as a covariate using the natural log-transformed AUC0-4. P-values are not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Ratio</param_type>
            <param_value>0.98</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.079</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Placebo was the Reference and each of the active doses was the Test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3425</p_value>
            <p_value_desc>Two-sided p-values are from ANCOVA model with treatment as a factor and baseline value as a covariate using the natural log-transformed AUC0-4. P-values are not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Ratio</param_type>
            <param_value>0.93</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.082</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Placebo was the Reference and each of the active doses was the Test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9670</p_value>
            <p_value_desc>Two-sided p-values are from ANCOVA model with treatment as a factor and baseline value as a covariate using the natural log-transformed AUC0-4. P-values are not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Ratio</param_type>
            <param_value>1.00</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.076</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Placebo was the Reference and each of the active doses was the Test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3190</p_value>
            <p_value_desc>Two-sided p-values are from ANCOVA model with treatment as a factor and baseline value as a covariate using the natural log-transformed AUC0-4. P-values are not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Ratio</param_type>
            <param_value>1.08</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.079</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes Relative to Baseline (Ratio) of AUC0-4 for C-Peptide Following MMTT on Day 14 - Part B</title>
        <description>Blood samples for analysis of insulin, C-peptide, glucagon and GLP-1 were collected at nominal time 0, 0.25, 0.5, 1, 1.5, 2, 3, 4 hours on Days -1 and 14 for all cohorts, and on Day 28 and follow-up visit for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B. AUC0-4 and natural log transformed AUC0-4 were calculated for each day.</description>
        <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 3, 4 hours on Days -1 and 14 for all cohorts, and on Day 28 and follow-up visit for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B.</time_frame>
        <population>All subjects administered PF-06291874 or placebo were included in PD analysis. Placebo subjects within each cohort in Part A or B were pooled into a single placebo group for the inpatient portion of the study. Data collected from placebo subjects during the outpatient portion of study (Day 28) were also pooled separately for Parts A and B.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06291874 15 mg</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 30 mg</title>
            <description>Participants received PF-06291874 30 mg orally once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 14 or 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Changes Relative to Baseline (Ratio) of AUC0-4 for C-Peptide Following MMTT on Day 14 - Part B</title>
          <description>Blood samples for analysis of insulin, C-peptide, glucagon and GLP-1 were collected at nominal time 0, 0.25, 0.5, 1, 1.5, 2, 3, 4 hours on Days -1 and 14 for all cohorts, and on Day 28 and follow-up visit for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B. AUC0-4 and natural log transformed AUC0-4 were calculated for each day.</description>
          <population>All subjects administered PF-06291874 or placebo were included in PD analysis. Placebo subjects within each cohort in Part A or B were pooled into a single placebo group for the inpatient portion of the study. Data collected from placebo subjects during the outpatient portion of study (Day 28) were also pooled separately for Parts A and B.</population>
          <units>Ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.19" spread="32" lower_limit="1.06" upper_limit="1.33"/>
                    <measurement group_id="O2" value="1.13" spread="217" lower_limit="1.03" upper_limit="1.24"/>
                    <measurement group_id="O3" value="1.05" lower_limit="0.95" upper_limit="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Placebo was the Reference and each of the active doses was the Test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1617</p_value>
            <p_value_desc>Two-sided p-values are from ANCOVA model with treatment as a factor and baseline value as a covariate using the natural log-transformed AUC0-4. P-values are not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Ratio</param_type>
            <param_value>1.14</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.095</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Placebo was the Reference and each of the active doses was the Test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3703</p_value>
            <p_value_desc>Two-sided p-values are from ANCOVA model with treatment as a factor and baseline value as a covariate using the natural log-transformed AUC0-4. P-values are not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Ratio</param_type>
            <param_value>1.08</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.084</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes Relative to Baseline (Ratio) of AUC0-4 for C-Peptide Following MMTT on Day 28</title>
        <description>Blood samples for analysis of insulin, C-peptide, glucagon and GLP-1 were collected at nominal time 0, 0.25, 0.5, 1, 1.5, 2, 3, 4 hours on Days -1 and 14 for all cohorts, and on Day 28 and follow-up visit for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B. AUC0-4 and natural log transformed AUC0-4 were calculated for each day.</description>
        <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 3, 4 hours on Days -1 and 14 for all cohorts, and on Day 28 and follow-up visit for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B.</time_frame>
        <population>All subjects administered PF-06291874 or placebo were included in PD analysis. Placebo subjects within each cohort in Part A or B were pooled into a single placebo group for the inpatient portion of the study. Data collected from placebo subjects during the outpatient portion of study (Day 28) were also pooled separately for Parts A and B.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 14 or 28 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 100 mg</title>
            <description>Participants received PF-06291874 100 mg orally once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Placebo - Part B</title>
            <description>Participants received placebo orally once daily for 14 or 28 days</description>
          </group>
          <group group_id="O4">
            <title>PF-06291874 30 mg</title>
            <description>Participants received PF-06291874 30 mg orally once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Changes Relative to Baseline (Ratio) of AUC0-4 for C-Peptide Following MMTT on Day 28</title>
          <description>Blood samples for analysis of insulin, C-peptide, glucagon and GLP-1 were collected at nominal time 0, 0.25, 0.5, 1, 1.5, 2, 3, 4 hours on Days -1 and 14 for all cohorts, and on Day 28 and follow-up visit for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B. AUC0-4 and natural log transformed AUC0-4 were calculated for each day.</description>
          <population>All subjects administered PF-06291874 or placebo were included in PD analysis. Placebo subjects within each cohort in Part A or B were pooled into a single placebo group for the inpatient portion of the study. Data collected from placebo subjects during the outpatient portion of study (Day 28) were also pooled separately for Parts A and B.</population>
          <units>Ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" spread="58" lower_limit="0.81" upper_limit="1.11"/>
                    <measurement group_id="O2" value="0.91" spread="28" lower_limit="0.82" upper_limit="1.00"/>
                    <measurement group_id="O3" value="0.79" spread="38" lower_limit="0.68" upper_limit="0.91"/>
                    <measurement group_id="O4" value="0.93" spread="178" lower_limit="0.84" upper_limit="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Placebo was the Reference and each of the active doses was the Test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6833</p_value>
            <p_value_desc>Two-sided p-values are from ANCOVA model with treatment as a factor and baseline value as a covariate using the natural log-transformed AUC0-4. P-values are not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Ratio</param_type>
            <param_value>0.95</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.119</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Placebo was the Reference and each of the active doses was the Test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1318</p_value>
            <p_value_desc>Two-sided p-values are from ANCOVA model with treatment as a factor and baseline value as a covariate using the natural log-transformed AUC0-4. P-values are not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Ratio</param_type>
            <param_value>1.18</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.112</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.41</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Values and Changes From Baseline in Fasting Plasma Glucose at at Days 2, 7, 14, 15, 21, 28 and 29 - Part A</title>
        <description>Fasting blood glucose samples were also collected on Days 0, 2, 7, and 15 for all cohorts, and on Days 21 and 29 for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B.</description>
        <time_frame>predose on Days 0,2,7,14,15,21,28,29</time_frame>
        <population>All subjects administered PF-06291874 or placebo were included in PD analysis. Placebo subjects within each cohort in Part A or B were pooled into a single placebo group for the inpatient portion of the study. Data collected from placebo subjects during the outpatient portion of study (Day 28) were also pooled separately for Parts A and B.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 14 or 28 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 5 mg</title>
            <description>Participants received PF-06291874 5 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PF-06291874 15 mg</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O4">
            <title>PF-06291874 50 mg</title>
            <description>Participants received PF-06291874 50 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O5">
            <title>PF-06291874 100 mg</title>
            <description>Participants received PF-06291874 100 mg orally once daily for 28 days</description>
          </group>
          <group group_id="O6">
            <title>PF-06291874 150 mg</title>
            <description>Participants received PF-06291874 150 mg orally once daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Values and Changes From Baseline in Fasting Plasma Glucose at at Days 2, 7, 14, 15, 21, 28 and 29 - Part A</title>
          <description>Fasting blood glucose samples were also collected on Days 0, 2, 7, and 15 for all cohorts, and on Days 21 and 29 for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B.</description>
          <population>All subjects administered PF-06291874 or placebo were included in PD analysis. Placebo subjects within each cohort in Part A or B were pooled into a single placebo group for the inpatient portion of the study. Data collected from placebo subjects during the outpatient portion of study (Day 28) were also pooled separately for Parts A and B.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165.8" spread="31.61"/>
                    <measurement group_id="O2" value="163.6" spread="32.43"/>
                    <measurement group_id="O3" value="173.1" spread="38.28"/>
                    <measurement group_id="O4" value="173.9" spread="45.67"/>
                    <measurement group_id="O5" value="150.6" spread="29.45"/>
                    <measurement group_id="O6" value="170.4" spread="41.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 absolute value</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167.0" spread="35.06"/>
                    <measurement group_id="O2" value="158.7" spread="32.08"/>
                    <measurement group_id="O3" value="152.3" spread="31.59"/>
                    <measurement group_id="O4" value="150.0" spread="31.71"/>
                    <measurement group_id="O5" value="139.4" spread="42.05"/>
                    <measurement group_id="O6" value="135.1" spread="31.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 changes from baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="16.60"/>
                    <measurement group_id="O2" value="-4.9" spread="14.37"/>
                    <measurement group_id="O3" value="-20.8" spread="13.54"/>
                    <measurement group_id="O4" value="-23.9" spread="23.36"/>
                    <measurement group_id="O5" value="-14.4" spread="32.29"/>
                    <measurement group_id="O6" value="-35.3" spread="14.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 absolute value</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="11"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161.4" spread="33.30"/>
                    <measurement group_id="O2" value="154.5" spread="32.07"/>
                    <measurement group_id="O3" value="147.9" spread="27.04"/>
                    <measurement group_id="O4" value="138.5" spread="33.56"/>
                    <measurement group_id="O5" value="122.5" spread="16.38"/>
                    <measurement group_id="O6" value="116.5" spread="21.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 changes from baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="11"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.4" spread="18.14"/>
                    <measurement group_id="O2" value="-9.1" spread="22.57"/>
                    <measurement group_id="O3" value="-25.2" spread="25.83"/>
                    <measurement group_id="O4" value="-37.4" spread="25.10"/>
                    <measurement group_id="O5" value="-35.6" spread="21.67"/>
                    <measurement group_id="O6" value="-38.4" spread="15.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 absolute value</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150.9" spread="33.95"/>
                    <measurement group_id="O2" value="144.4" spread="33.67"/>
                    <measurement group_id="O3" value="133.3" spread="39.57"/>
                    <measurement group_id="O4" value="131.5" spread="28.68"/>
                    <measurement group_id="O5" value="112.9" spread="17.54"/>
                    <measurement group_id="O6" value="121.3" spread="30.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 changes from baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.8" spread="29.96"/>
                    <measurement group_id="O2" value="-19.2" spread="21.45"/>
                    <measurement group_id="O3" value="-39.8" spread="34.07"/>
                    <measurement group_id="O4" value="-42.4" spread="29.56"/>
                    <measurement group_id="O5" value="-37.7" spread="19.46"/>
                    <measurement group_id="O6" value="-49.1" spread="18.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 absolute value</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="11"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155.4" spread="33.08"/>
                    <measurement group_id="O2" value="150.9" spread="37.64"/>
                    <measurement group_id="O3" value="131.6" spread="25.96"/>
                    <measurement group_id="O4" value="132.7" spread="31.67"/>
                    <measurement group_id="O5" value="120.4" spread="22.15"/>
                    <measurement group_id="O6" value="122.7" spread="30.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 changes from baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="11"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.4" spread="27.51"/>
                    <measurement group_id="O2" value="-16.2" spread="21.64"/>
                    <measurement group_id="O3" value="-41.5" spread="33.08"/>
                    <measurement group_id="O4" value="-44.2" spread="33.10"/>
                    <measurement group_id="O5" value="-33.4" spread="24.46"/>
                    <measurement group_id="O6" value="-47.7" spread="19.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21 absolute value</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161.2" spread="38.22"/>
                    <measurement group_id="O5" value="128.5" spread="26.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21 changes from baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="30.57"/>
                    <measurement group_id="O5" value="-24.2" spread="31.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 absolute value</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163.7" spread="26.90"/>
                    <measurement group_id="O5" value="122.4" spread="20.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 changes from baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="22.52"/>
                    <measurement group_id="O5" value="-28.2" spread="15.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 absolute value</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166.5" spread="31.56"/>
                    <measurement group_id="O5" value="129.6" spread="23.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 changes from baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="21.17"/>
                    <measurement group_id="O5" value="-24.2" spread="21.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Values and Changes From Baseline in Fasting Plasma Glucose at Days 2, 7, 14, 15, 21, 28 and 29 - Part B</title>
        <description>Fasting blood glucose samples were also collected on Days 0, 2, 7, and 15 for all cohorts, and on Days 21 and 29 for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B.</description>
        <time_frame>Days 0,2,7,14,15,21,28,29</time_frame>
        <population>All subjects administered PF-06291874 or placebo were included in PD analysis. Placebo subjects within each cohort in Part A or B were pooled into a single placebo group for the inpatient portion of the study. Data collected from placebo subjects during the outpatient portion of study (Day 28) were also pooled separately for Parts A and B.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 14 or 28 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 15 mg</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PF-06291874 30 mg</title>
            <description>Participants received PF-06291874 30 mg orally once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Values and Changes From Baseline in Fasting Plasma Glucose at Days 2, 7, 14, 15, 21, 28 and 29 - Part B</title>
          <description>Fasting blood glucose samples were also collected on Days 0, 2, 7, and 15 for all cohorts, and on Days 21 and 29 for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B.</description>
          <population>All subjects administered PF-06291874 or placebo were included in PD analysis. Placebo subjects within each cohort in Part A or B were pooled into a single placebo group for the inpatient portion of the study. Data collected from placebo subjects during the outpatient portion of study (Day 28) were also pooled separately for Parts A and B.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156.0" spread="37.72"/>
                    <measurement group_id="O2" value="163.9" spread="31.43"/>
                    <measurement group_id="O3" value="154.3" spread="38.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 absolute value</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133.9" spread="26.73"/>
                    <measurement group_id="O2" value="147.6" spread="32.25"/>
                    <measurement group_id="O3" value="129.7" spread="28.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 changes from baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.8" spread="10.79"/>
                    <measurement group_id="O2" value="-16.3" spread="9.05"/>
                    <measurement group_id="O3" value="-29.7" spread="18.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 absolute value</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125.9" spread="32.13"/>
                    <measurement group_id="O2" value="134.4" spread="32.15"/>
                    <measurement group_id="O3" value="114.4" spread="20.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 changes from baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.0" spread="25.32"/>
                    <measurement group_id="O2" value="-29.5" spread="15.47"/>
                    <measurement group_id="O3" value="-41.6" spread="36.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 absolute value</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.3" spread="40.08"/>
                    <measurement group_id="O2" value="128.6" spread="36.04"/>
                    <measurement group_id="O3" value="108.9" spread="24.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 changes from baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.0" spread="35.02"/>
                    <measurement group_id="O2" value="-35.3" spread="18.32"/>
                    <measurement group_id="O3" value="-45.3" spread="32.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 absolute value</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.7" spread="37.44"/>
                    <measurement group_id="O2" value="133.4" spread="36.28"/>
                    <measurement group_id="O3" value="115.4" spread="32.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 changes from baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.6" spread="33.01"/>
                    <measurement group_id="O2" value="-30.5" spread="19.31"/>
                    <measurement group_id="O3" value="-38.8" spread="33.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21 absolute value</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136.9" spread="34.54"/>
                    <measurement group_id="O3" value="131.5" spread="34.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21 changes from baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" spread="26.23"/>
                    <measurement group_id="O3" value="-18.3" spread="37.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 absolute value</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.3" spread="21.84"/>
                    <measurement group_id="O3" value="113.3" spread="34.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 changes from baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.4" spread="33.19"/>
                    <measurement group_id="O3" value="-41.0" spread="44.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 absolute value</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127.9" spread="15.87"/>
                    <measurement group_id="O3" value="127.5" spread="28.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 changes from baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.8" spread="11.53"/>
                    <measurement group_id="O3" value="-26.1" spread="28.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Values and Changes From Baseline in Fasting Plasma Insulin at Days 14 and 28 - Part A</title>
        <description>Fasting blood insulin samples were collected on Days -1, 14 and 28 for all cohorts, and on Day 28 for PF-06291874 100 mg Part A. Baseline was defined as the value on Day -1.</description>
        <time_frame>Days -1, 14, 28</time_frame>
        <population>All subjects administered PF-06291874 or placebo were included in PD analysis. Placebo subjects within each cohort in Part A or B were pooled into a single placebo group for the inpatient portion of the study. Data collected from placebo subjects during the outpatient portion of study (Day 28) were also pooled separately for Parts A and B.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 14 or 28 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 5 mg</title>
            <description>Participants received PF-06291874 5 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PF-06291874 15 mg</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O4">
            <title>PF-06291874 50 mg</title>
            <description>Participants received PF-06291874 50 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O5">
            <title>PF-06291874 100 mg</title>
            <description>Participants received PF-06291874 100 mg orally once daily for 28 days</description>
          </group>
          <group group_id="O6">
            <title>PF-06291874 150 mg</title>
            <description>Participants received PF-06291874 150 mg orally once daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Values and Changes From Baseline in Fasting Plasma Insulin at Days 14 and 28 - Part A</title>
          <description>Fasting blood insulin samples were collected on Days -1, 14 and 28 for all cohorts, and on Day 28 for PF-06291874 100 mg Part A. Baseline was defined as the value on Day -1.</description>
          <population>All subjects administered PF-06291874 or placebo were included in PD analysis. Placebo subjects within each cohort in Part A or B were pooled into a single placebo group for the inpatient portion of the study. Data collected from placebo subjects during the outpatient portion of study (Day 28) were also pooled separately for Parts A and B.</population>
          <units>µIU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.82" spread="3.26"/>
                    <measurement group_id="O2" value="9.84" spread="5.12"/>
                    <measurement group_id="O3" value="11.04" spread="6.06"/>
                    <measurement group_id="O4" value="7.34" spread="3.60"/>
                    <measurement group_id="O5" value="10.77" spread="6.62"/>
                    <measurement group_id="O6" value="9.64" spread="5.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 absolute value</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.93" spread="3.91"/>
                    <measurement group_id="O2" value="9.83" spread="4.01"/>
                    <measurement group_id="O3" value="10.33" spread="4.96"/>
                    <measurement group_id="O4" value="5.61" spread="2.72"/>
                    <measurement group_id="O5" value="9.09" spread="4.27"/>
                    <measurement group_id="O6" value="8.98" spread="5.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 changes from baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.88" spread="2.81"/>
                    <measurement group_id="O2" value="0.00" spread="3.86"/>
                    <measurement group_id="O3" value="-0.37" spread="3.46"/>
                    <measurement group_id="O4" value="-1.73" spread="1.52"/>
                    <measurement group_id="O5" value="-1.68" spread="3.43"/>
                    <measurement group_id="O6" value="-0.66" spread="2.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 absolute value</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.53" spread="4.20"/>
                    <measurement group_id="O5" value="9.30" spread="3.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 changes from baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.82" spread="4.35"/>
                    <measurement group_id="O5" value="-1.46" spread="3.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Values and Changes From Baseline in Fasting Plasma Insulin at Days 14 and 28 - Part B</title>
        <description>Fasting blood insulin samples were collected on Days -1, 14 and 28 for all cohorts, and on Day 28 for PF-06291874 30 mg Part B. Baseline was defined as the value on Day -1.</description>
        <time_frame>Days -1, 14, 28</time_frame>
        <population>All subjects administered PF-06291874 or placebo were included in PD analysis. Placebo subjects within each cohort in Part A or B were pooled into a single placebo group for the inpatient portion of the study. Data collected from placebo subjects during the outpatient portion of study (Day 28) were also pooled separately for Parts A and B.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 14 or 28 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 15 mg</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PF-06291874 30 mg</title>
            <description>Participants received PF-06291874 30 mg orally once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Values and Changes From Baseline in Fasting Plasma Insulin at Days 14 and 28 - Part B</title>
          <description>Fasting blood insulin samples were collected on Days -1, 14 and 28 for all cohorts, and on Day 28 for PF-06291874 30 mg Part B. Baseline was defined as the value on Day -1.</description>
          <population>All subjects administered PF-06291874 or placebo were included in PD analysis. Placebo subjects within each cohort in Part A or B were pooled into a single placebo group for the inpatient portion of the study. Data collected from placebo subjects during the outpatient portion of study (Day 28) were also pooled separately for Parts A and B.</population>
          <units>µIU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.66" spread="2.59"/>
                    <measurement group_id="O2" value="14.49" spread="9.70"/>
                    <measurement group_id="O3" value="9.69" spread="4.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 absolute value</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.08" spread="3.81"/>
                    <measurement group_id="O2" value="12.57" spread="8.63"/>
                    <measurement group_id="O3" value="9.82" spread="4.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 changes from baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.49" spread="2.96"/>
                    <measurement group_id="O2" value="-1.13" spread="1.75"/>
                    <measurement group_id="O3" value="-0.25" spread="4.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 absolute value</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.96" spread="3.58"/>
                    <measurement group_id="O3" value="10.43" spread="4.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 changes from baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.44" spread="2.92"/>
                    <measurement group_id="O3" value="1.41" spread="4.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Lipid Parameters (mg/dL) by Treatment Group on Days 14 and 28 - Part A</title>
        <description>Blood samples (3.5 mL) for all lipids and 2 mL for ApoB100 were collected at Hour 0 Day 1, Day 7 prior to breakfast, Hour 0 Day 14 for all cohorts; Days 21 and 28 for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B.</description>
        <time_frame>Days 0,14 and 28</time_frame>
        <population>All subjects administered PF-06291874 or placebo were included in PD analysis. Placebo subjects within each cohort in Part A or B were pooled into a single placebo group for the inpatient portion of the study. Data collected from placebo subjects during the outpatient portion of study (Day 28) were also pooled separately for Parts A and B.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 14 or 28 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 5 mg</title>
            <description>Participants received PF-06291874 5 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PF-06291874 15 mg</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O4">
            <title>PF-06291874 50 mg</title>
            <description>Participants received PF-06291874 50 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O5">
            <title>PF-06291874 100 mg</title>
            <description>Participants received PF-06291874 100 mg orally once daily for 28 days</description>
          </group>
          <group group_id="O6">
            <title>PF-06291874 150 mg</title>
            <description>Participants received PF-06291874 150 mg orally once daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Lipid Parameters (mg/dL) by Treatment Group on Days 14 and 28 - Part A</title>
          <description>Blood samples (3.5 mL) for all lipids and 2 mL for ApoB100 were collected at Hour 0 Day 1, Day 7 prior to breakfast, Hour 0 Day 14 for all cohorts; Days 21 and 28 for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B.</description>
          <population>All subjects administered PF-06291874 or placebo were included in PD analysis. Placebo subjects within each cohort in Part A or B were pooled into a single placebo group for the inpatient portion of the study. Data collected from placebo subjects during the outpatient portion of study (Day 28) were also pooled separately for Parts A and B.</population>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Cholesterol-Day 14 Mean Percent Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.6" spread="6.7"/>
                    <measurement group_id="O2" value="-5.6" spread="6.6"/>
                    <measurement group_id="O3" value="-5.6" spread="14.1"/>
                    <measurement group_id="O4" value="1.7" spread="11.8"/>
                    <measurement group_id="O5" value="0.0" spread="9.9"/>
                    <measurement group_id="O6" value="9.7" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Cholesterol-Day28 Mean Percent Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="13.0"/>
                    <measurement group_id="O5" value="4.3" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL Cholesterol -Day 14 Mean Percent Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.6" spread="12.6"/>
                    <measurement group_id="O2" value="-9.4" spread="10.8"/>
                    <measurement group_id="O3" value="-6.4" spread="16.7"/>
                    <measurement group_id="O4" value="2.0" spread="17.9"/>
                    <measurement group_id="O5" value="-0.4" spread="12.2"/>
                    <measurement group_id="O6" value="12.0" spread="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL Cholesterol -Day28 Mean Percent Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="16.8"/>
                    <measurement group_id="O5" value="4.7" spread="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL Cholesterol -Day 14 Mean Percent Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.4" spread="5.6"/>
                    <measurement group_id="O2" value="-5.2" spread="11.3"/>
                    <measurement group_id="O3" value="-6.5" spread="9.9"/>
                    <measurement group_id="O4" value="-4.0" spread="9.7"/>
                    <measurement group_id="O5" value="-1.5" spread="8.4"/>
                    <measurement group_id="O6" value="2.6" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL Cholesterol -Day28 Mean Percent Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="8.5"/>
                    <measurement group_id="O5" value="0.2" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides -Day 14 Mean Percent Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.9" spread="15.2"/>
                    <measurement group_id="O2" value="6.4" spread="21.4"/>
                    <measurement group_id="O3" value="10.3" spread="30.5"/>
                    <measurement group_id="O4" value="11.6" spread="33.9"/>
                    <measurement group_id="O5" value="-0.2" spread="23.9"/>
                    <measurement group_id="O6" value="18.3" spread="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides -Day28 Mean Percent Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="24.5"/>
                    <measurement group_id="O5" value="6.4" spread="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ApoB100 -Day 14 Mean Percent Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.2" spread="6.8"/>
                    <measurement group_id="O2" value="-5.6" spread="9.9"/>
                    <measurement group_id="O3" value="-6.1" spread="14.8"/>
                    <measurement group_id="O4" value="1.4" spread="10.8"/>
                    <measurement group_id="O5" value="-0.2" spread="10.3"/>
                    <measurement group_id="O6" value="9.0" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ApoB100 -Day 28 Mean Percent Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="12.6"/>
                    <measurement group_id="O5" value="2.7" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Lipid Parameters (mg/dL) by Treatment Group on Days 14 and 28 - Part B</title>
        <description>Blood samples (3.5 mL) for all lipids and 2 mL for ApoB100 were collected at Hour 0 Day 1, Day 7 prior to breakfast, Hour 0 Day 14 for all cohorts; Days 21 and 28 for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B.</description>
        <time_frame>Days 0,14 and 28</time_frame>
        <population>All subjects administered PF-06291874 or placebo were included in PD analysis. Placebo subjects within each cohort in Part A or B were pooled into a single placebo group for the inpatient portion of the study. Data collected from placebo subjects during the outpatient portion of study (Day 28) were also pooled separately for Parts A and B.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 14 or 28 days</description>
          </group>
          <group group_id="O2">
            <title>PF-06291874 15 mg</title>
            <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PF-06291874 30 mg</title>
            <description>Participants received PF-06291874 30 mg orally once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Lipid Parameters (mg/dL) by Treatment Group on Days 14 and 28 - Part B</title>
          <description>Blood samples (3.5 mL) for all lipids and 2 mL for ApoB100 were collected at Hour 0 Day 1, Day 7 prior to breakfast, Hour 0 Day 14 for all cohorts; Days 21 and 28 for PF-06291874 100 mg Part A and PF-06291874 30 mg Part B.</description>
          <population>All subjects administered PF-06291874 or placebo were included in PD analysis. Placebo subjects within each cohort in Part A or B were pooled into a single placebo group for the inpatient portion of the study. Data collected from placebo subjects during the outpatient portion of study (Day 28) were also pooled separately for Parts A and B.</population>
          <units>Percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Cholesterol-Day 14 Mean Percent Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" spread="12.6"/>
                    <measurement group_id="O2" value="-0.6" spread="11.9"/>
                    <measurement group_id="O3" value="-4.7" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Cholesterol-Day28 Mean Percent Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" spread="25.3"/>
                    <measurement group_id="O3" value="-1.5" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL Cholesterol -Day 14 Mean Percent Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.5" spread="15.6"/>
                    <measurement group_id="O2" value="1.50" spread="21.5"/>
                    <measurement group_id="O3" value="-7.5" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL Cholesterol -Day28 Mean Percent Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7" spread="28.8"/>
                    <measurement group_id="O3" value="-0.7" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL Cholesterol -Day 14 Mean Percent Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.7" spread="12.9"/>
                    <measurement group_id="O2" value="-5.8" spread="12.2"/>
                    <measurement group_id="O3" value="-2.9" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL Cholesterol -Day28 Mean Percent Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="13.6"/>
                    <measurement group_id="O3" value="1.7" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides -Day 14 Mean Percent Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.6" spread="15.7"/>
                    <measurement group_id="O2" value="-6.0" spread="17.5"/>
                    <measurement group_id="O3" value="-8.4" spread="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides -Day28 Mean Percent Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="60.9"/>
                    <measurement group_id="O3" value="-1.9" spread="23.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ApoB100 -Day 14 Mean Percent Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="12.4"/>
                    <measurement group_id="O2" value="-4.1" spread="10.3"/>
                    <measurement group_id="O3" value="-5.6" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ApoB100 -Day 28 Mean Percent Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" spread="21.2"/>
                    <measurement group_id="O3" value="-1.1" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Part A: Placebo</title>
          <description>Participants received placebo matched to PF-06291874 orally once daily for 14 or 28 days</description>
        </group>
        <group group_id="E2">
          <title>Part A: PF-06291874 5 mg</title>
          <description>Participants received PF-06291874 5 milligram (mg) orally once daily for 14 days</description>
        </group>
        <group group_id="E3">
          <title>Part A: PF-06291874 15 mg</title>
          <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
        </group>
        <group group_id="E4">
          <title>Part A: PF-06291874 50 mg</title>
          <description>Participants received PF-06291874 50 mg orally once daily for 14 days</description>
        </group>
        <group group_id="E5">
          <title>Part A: PF-06291874 100 mg</title>
          <description>Participants received PF-06291874 100 mg orally once daily for 28 days</description>
        </group>
        <group group_id="E6">
          <title>Part A: PF-06291874 150 mg</title>
          <description>Participants received PF-06291874 150 mg orally once daily for 14 days</description>
        </group>
        <group group_id="E7">
          <title>Part B: Placebo</title>
          <description>Participants received placebo matched to PF-06291874 orally once daily for 14 or 28 days</description>
        </group>
        <group group_id="E8">
          <title>Part B: PF-06291874 15 mg</title>
          <description>Participants received PF-06291874 15 mg orally once daily for 14 days</description>
        </group>
        <group group_id="E9">
          <title>Part B: PF-06291874 30 mg</title>
          <description>Participants received PF-06291874 30 mg orally once daily for 28 days</description>
        </group>
        <group group_id="E10">
          <title>Total</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="53" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Normochromic normocytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Chromatopsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="9" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site bruise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Vessel puncture site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Urinary hesitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

